Skip to main content

Second-Generation Antihistamines

Actions and Efficacy in the Management of Allergic Disorders

Drugs volume 65, pages 341–384 (2005)Cite this article

Abstract

Antihistamines are useful medications for the treatment of a variety of allergic disorders. Second-generation antihistamines avidly and selectively bind to peripheral histamine H1 receptors and, consequently, provide gratifying relief of histamine-mediated symptoms in a majority of atopic patients. This tight receptor specificity additionally leads to few effects on other neuronal or hormonal systems, with the result that adverse effects associated with these medications, with the exception of noticeable sedation in about 10% of cetirizine-treated patients, resemble those of placebo overall. Similarly, serious adverse drug reactions and interactions are uncommon with these medicines. Therapeutic interchange to one of the available second-generation antihistamines is a reasonable approach to limiting an institutional formulary, and adoption of such a policy has proven capable of creating substantial cost savings. Differences in overall efficacy and safety between available second-generation antihistamines, when administered in equivalent dosages, are not large. However, among the antihistamines presently available, fexofenadine may offer the best overall balance of effectiveness and safety, and this agent is an appropriate selection for initial or switch therapy for most patients with mild or moderate allergic symptoms. Cetirizine is the most potent antihistamine available and has been subjected to more clinical study than any other. This agent is appropriate for patients proven unresponsive to other antihistamines and for those with the most severe symptoms who might benefit from antihistamine treatment of the highest potency that can be dose-titrated up to maximal intensity.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 49.95

Price includes VAT (USA)
Tax calculation will be finalised during checkout.

Table I
Table II
Table III
Table IV
Table V
Table VI
Table VII
Table VIII
Table IX
Table X
Table XI
Table XII
Table XIII
Table XIV
Table XV

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Slater JM, Zechnich AD, Haxby DG. Second-generation anti-histamines: a comparative review. Drugs 1999; 57: 31–47

    PubMed  CAS  Article  Google Scholar 

  2. Simons FER. Comparative pharmacology of H1 antihistamines: clinical relevance. Am J Med 2002; 113 Suppl. 9A: 38–46

    Article  Google Scholar 

  3. Best CH, Dale HH, Dudley HW, et al. The nature of the vasodilator constituents of certain tissue extracts. J Physiol 1927; 62: 397–417

    PubMed  CAS  Google Scholar 

  4. Dvorak AM. Ultrastructural localization of histamine in human basophils and mast cells: changes associated with anaphylactic degranulation and recovery demonstrated with a diamine oxidase-gold probe. Allergy 1997; 52 Suppl. 34: 14–24

    PubMed  CAS  Article  Google Scholar 

  5. Dale HH, Laidlaw PP. The physiological action of β-iminazolylethylamine. J Physiol 1910; 41: 318–44

    PubMed  CAS  Google Scholar 

  6. Marshall Jr GD. Therapeutic options in allergic disease: antihistamines as systemic antiallergic agents. J Allergy Clin Immunol 2000; 106 (5 Suppl.): 303–9

    Article  Google Scholar 

  7. Brown NJ, Roberts II LJ. Histamine, bradykinin, and their antagonists. In: Hardman JG, Limbird LE, Gilman AGG, editors. Goodman & Gilman’s the pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill, 2001: 645–67

    Google Scholar 

  8. Simons FER, Simons KJ. The pharmacology and use of H1-receptor-antagonist drugs. N Engl J Med 1994; 330: 1663–70

    PubMed  CAS  Article  Google Scholar 

  9. Liu C, Ma X-J, Jiang X, et al. Cloning and pharmacological characterization of a fourth histamine receptor (H4) expressed in bone marrow. Mol Pharmacol 2001; 59: 420–6

    PubMed  CAS  Google Scholar 

  10. Ash ASF, Schild HO. Receptors mediating some actions of histamine. Br J Pharmacol 1966; 27: 427–39

    CAS  Google Scholar 

  11. Bovet D. Introduction to antihistamine agents and Antergan derivatives. Ann N Y Acad Sci 1950; 50: 1089–126

    PubMed  CAS  Article  Google Scholar 

  12. Anthes J, Eckel S, Richard C, et al. Characterization of [3H] desloratadine at the human H1 receptor [abstract no. 526]. J Allergy Clin Immunol 2001; 107 Suppl. 2: 160

    Google Scholar 

  13. Anthes JC, Gilchrest H, Richard C, et al. Biochemical characterization of desloratadine, a potent antagonist of the human histamine H1 receptor. Eur J Pharmacol 2002; 449: 229–37

    PubMed  CAS  Article  Google Scholar 

  14. Christophe B, Carlier B, Gillard M, et al. Histamine H1 receptor antagonism by cetirizine in isolated guinea pig tissues: influence of receptor reserve and dissociation kinetics. Eur J Pharmacol 2003; 470: 87–94

    PubMed  CAS  Article  Google Scholar 

  15. Gillard M, van der Perren C, Moguilevsky N, et al. Binding characteristics of cetirizine and levocetirizine to human H1 histamine receptors: contribution of Lys191 and Thr194. Mol Pharmacol 2002; 61: 391–9

    PubMed  CAS  Article  Google Scholar 

  16. Shishoo CJ, Shirsath VS, Tathod IS, et al. Design, synthesis and antihistaminic (H1) activity of some condensed 2-(substituted) arylaminoethylpyrimidin-4(3H)-ones. Arzneimittelforschung 2001; 51: 221–31

    PubMed  CAS  Google Scholar 

  17. Snyder SH, Snowman AM. Receptor effects of cetirizine. Ann Allergy 1987; 59 (6 Pt 2): 4–8

    PubMed  CAS  Google Scholar 

  18. Weiland K, Ter Laak AM, Smit MJ, et al. Mutational analysis of the antagonist-binding site of the histamine H1 receptor. J Biol Chem 1999; 274: 29994–30000

    Article  Google Scholar 

  19. Gillard M, Christophe B, Wels B, et al. H1 antagonists: receptor affinity versus selectivity. Inflamm Res 2003; 52 Suppl. 1: 49–50

    Article  Google Scholar 

  20. Howarth PH, Salagean M, Dokic D. Allergic rhinitis: not purely a histamine-related disease. Allergy 2000; 55 Suppl. 64: 7–16

    PubMed  Article  Google Scholar 

  21. Arnold R, König B, König W. G-proteins in allergy. Clin Exp Allergy 1997; 27 Suppl. 2: 1–7

    PubMed  CAS  Article  Google Scholar 

  22. Canonica GW, Ciprandi G, Passalacqua G, et al. Molecular events in allergic inflammation: experimental models and possible modulation. Allergy 1997; 52 Suppl. 34: 25–30

    PubMed  CAS  Article  Google Scholar 

  23. Charlesworth EN. The role of basophils and mast cells in acute and late reactions in the skin. Allergy 1997; 52 Suppl. 34: 31–43

    PubMed  CAS  Article  Google Scholar 

  24. Hayashi S, Hashimoto S. Anti-inflammatory actions of new antihistamines. Clin Exp Allergy 1999; 29: 1593–6

    PubMed  CAS  Article  Google Scholar 

  25. Walsh GM. The clinical relevance of the anti-inflammatory properties of antihistamines. Allergy 2000; 55 Suppl. 60: 53–61

    PubMed  Article  Google Scholar 

  26. Gibbs BF, Vollrath IB, Albrecht C, et al. Inhibition of interleukin-4 and interleukinn-13 release from immunologically activated human basophils due to the actions of anti-allergic drugs. Naunyn Schmiedebergs Arch Pharmacol 1998; 357: 573–8

    PubMed  CAS  Article  Google Scholar 

  27. Amon U, Amon S, Gibbs BF. In vitro studies with fexofenadine, a new nonsedating histamine H1 receptor antagonist, on isolated human basophils. Inflamm Res 2000; 49 Suppl. 1: 13–4

    Article  Google Scholar 

  28. Schroeder JT, Schleimer RP, Lichtenstein LM, et al. Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine. Clin Exp Allergy 2001; 31: 1369–77

    PubMed  CAS  Article  Google Scholar 

  29. Kalayci Ö, Saraclar Y, Adalioglu G, et al. The effect of cetirizine on sulfidoleukotriene production by leukocytes in children with allergic rhinitis. Allergy 1995; 50: 964–9

    PubMed  CAS  Article  Google Scholar 

  30. Genovese A, Patella V, De Crescenzo G, et al. Loratadine and desethoxylcarbonyl-loratadine inhibit the immunological release of mediators from human FcεRI+ cells. Clin Exp Allergy 1997; 27: 559–67

    PubMed  CAS  Article  Google Scholar 

  31. Piacentini GL, Mazzi P, Vinco S, et al. The effect of cetirizine on the integrin-dependent respiratory burst of normodense eosinophils. J Asthma 1996; 33: 417–23

    PubMed  CAS  Article  Google Scholar 

  32. Sedgwick JB, Busse WW. Inhibitory effect of cetirizine on cytokine-enhanced in vitro eosinophil survival. Ann Allergy Asthma Immunol 1997; 78: 581–5

    PubMed  CAS  Article  Google Scholar 

  33. Walsh GM, Moqbel R, Hartneil A, et al. Effects of cetirizine on human eosinophil and neutrophil activation in vitro. Int Arch Allergy Immunol 1991; 85: 158–62

    Article  Google Scholar 

  34. Okada C, Eda R, Miyagawa H, et al. Effect of cetirizine on human eosinophil Superoxide generation, eosinophil chemotaxis and eosinophil peroxidase in vitro. Int Arch Allergy Immunol 1994; 103: 384–90

    PubMed  CAS  Article  Google Scholar 

  35. Fadel R, Rassemont DR, Herpin-Richard N, et al. Eosinophil infiltration: effects of H1 antihistamines. J Am Acad Dermatol 1991; 24: 1094–6

    PubMed  CAS  Article  Google Scholar 

  36. De Vos C, Joseph M, Leprevost C, et al. Inhibition of human eosinophil chemotaxis and of the IgE-dependent stimulation of human blood platelets by cetirizine. Int Arch Allergy Immunol 1989; 88: 212–5

    Article  Google Scholar 

  37. Leprevost C, Capron M, De Vos C, et al. Inhibition of eosinophil chemotaxis by a new antiallergic compound (cetirizine). Int Arch Allergy Immunol 1988; 87: 9–13

    CAS  Article  Google Scholar 

  38. van Epps DE, Kutvirt SG, Potter JW. In vitro effects of cetirizine and histamine on human neutrophil function. Ann Allergy Asthma Immunol 1987; 59: 13–9

    Google Scholar 

  39. Eda R, Sugiyama H, Hopp RJ, et al. Effect of loratadine on human eosinophil function in vitro. Ann Allergy Asthma Immunol 1993; 71: 373–8

    CAS  Google Scholar 

  40. Letari O, Miozzo A, Folco G, et al. Effects of loratadine on cytosolic Ca2+ levels and leukotriene release: novel mechanisms of action independent of the anti-histamine activity. Eur J Pharmacol 1994; 266: 219–27

    PubMed  CAS  Article  Google Scholar 

  41. Lippert U, Möller A, Welker P, et al. Inhibition of cytokine secretion from human leukemic mast cells and basophils by H1- and H2-receptor antagonists. Exp Dermatol 2000; 9: 118–24

    PubMed  CAS  Article  Google Scholar 

  42. Cheria-Sammari S, Aloui R, Gormand F, et al. Leukotriene B4 production by blood neutrophils in allergic rhinitis: effects of cetirizine. Clin Exp Allergy 1995; 25: 729–36

    PubMed  CAS  Article  Google Scholar 

  43. Ohtani T, Aiba S, Mizuashi M, et al. Evaluation of the efficacy of antihistamines using human monocyte-derived dendritic cells stimulated with histamine. J Am Acad Dermatol 2003; 49: 234–42

    PubMed  Article  Google Scholar 

  44. Rihoux J-P, Masliah J, Bereziat G, et al. G proteins as biological targets for anti-allergic drugs? Int Arch Allergy Immunol 1997; 113: 339–41

    PubMed  CAS  Article  Google Scholar 

  45. Köller M, Hilger RA, Rihoux J-P, et al. Cetirizine exerts anti-inflammatory effects on human neutrophils. Int Arch Allergy Immunol 1996; 110: 52–6

    PubMed  Article  Google Scholar 

  46. Asano K, Kanai K, Suzaki H. Suppressive activity of fexofenadine hydrochloride on thymus- and activation-regulated chemokine production from human peripheral blood leukocytes in response to antigenic stimulation in vitro. Int Arch Allergy Immunol 2004; 132: 267–75

    Article  CAS  Google Scholar 

  47. Ciprandi G, Pronzato C, Ricca V, et al. Loratadine treatment of rhinitis due to pollen allergy reduces epithelial ICAM-1 expression. Clin Exp Allergy 1997; 27: 1175–83

    PubMed  CAS  Article  Google Scholar 

  48. Fasce L, Ciprandi G, Pronzato C, et al. Cetirizine reduces ICAM-1 on epithelial cells during nasal minimal persistent inflammation in asymptomatic children with mite-allergic asthma. Int Arch Allergy Immunol 1996; 109: 272–6

    PubMed  CAS  Article  Google Scholar 

  49. Küsters S, Schuligoi R, Hüttenbrink K-B, et al. Effects of antihistamines on leukotriene and cytokine release from dispersed nasal polyp cells. Arzneimittelforschung 2002; 52: 97–102

    PubMed  Google Scholar 

  50. Jacobi HH, Skov PS, Poulsen LK, et al. Histamine and tryptase in nasal lavage fluid after allergen challenge: effect of 1 week of pretreatment with intranasal azelastine or systemic cetirizine. J Allergy Clin Immunol 1999; 103: 768–72

    PubMed  CAS  Article  Google Scholar 

  51. Naclerio RM. Effects of antihistamines on inflammatory mediators. Ann Allergy 1993; 71: 292–5

    PubMed  CAS  Google Scholar 

  52. Naclerio RM. The effect of antihistamines on the immediate allergic response: a comparative review. Otolaryngol Head Neck Surg 1993; 108: 723–30

    PubMed  CAS  Google Scholar 

  53. Togias AG, Proud D, Kagey-Sobotka A, et al. In vivo and in vitro effects of antihistamines on mast cell mediator release: a potentially important property in the treatment of allergic disease. Ann Allergy 1989; 63: 465–9

    PubMed  CAS  Google Scholar 

  54. Wang D, Clement P, Smitz J. Effect of H1 and H2 antagonists on nasal symptoms and mediator release in atopic patients after nasal allergen challenge during pollen season. Acta Otolaryngol 1996; 116: 91–6

    PubMed  CAS  Article  Google Scholar 

  55. Cagnoni F, Oddera S, Semino C, et al. Cetirizine-induced downregulation of airway fibroblast proliferation and function: a rationale for a different approach to allergy treatment? Immunol Lett 2000; 72: 31–4

    PubMed  CAS  Article  Google Scholar 

  56. Ciprandi G, Tosca M-A, Milanese M, et al. Cetirizine reduces cytokines and inflammatory cells in children with perennial allergic rhinitis. Eur Ann Allergy Clin Immunol 2004; 36: 237–40

    PubMed  CAS  Google Scholar 

  57. Papi A, Papadopoulos NG, Stanciu LA, et al. Effect of desloratadine and loratadine on rhinovirus-induced intercellular adhesion molecule 1 upregulation and promoter activation in respiratory epithelial cells. J Allergy Clin Immunol 2001; 108: 221–8

    PubMed  CAS  Article  Google Scholar 

  58. Vignola AM, Crampette L, Mondain M, et al. Inhibitory activity of loratadine and descarboethoxyloratadine on expression of ICAM-1 and HLA-DR by nasal epithelial cells. Allergy 1995; 50: 200–3

    PubMed  CAS  Article  Google Scholar 

  59. Abdelaziz MM, Devalia JL, Khair OA, et al. Effect of fexofenadine on eosinophil-induced changes in epithelial permeability and cytokine release from nasal epithelial cells of patients with seasonal allergic rhinitis. J Allergy Clin Immunol 1998; 101: 410–20

    PubMed  CAS  Article  Google Scholar 

  60. Terrien M-H, Rahm F, Fellrath J-M, et al. Comparison of the effects of terfenadine with fexofenadine on nasal provocation tests with allergen. J Allergy Clin Immunol 1999; 103: 1025–30

    PubMed  CAS  Article  Google Scholar 

  61. Campbell A, Chanal I, Czarlewski W, et al. Reduction of soluble ICAM-1 levels in nasal secretion by H1-blockers in seasonal allergic rhinitis. Allergy 1997; 52: 1022–5

    PubMed  CAS  Article  Google Scholar 

  62. Muether PS, Gwaltney Jr JM. Variant effect of first- and second-generation antihistamines as clues to their mechanism of action on the sneeze reflex in the common cold. Clin Infect Dis 2001; 33: 1483–8

    PubMed  CAS  Article  Google Scholar 

  63. Baroody FM, Gungor A, De Tinio M, et al. Comparison of the response to histamine challenge of the nose and the maxillary sinus: effect of loratadine. J Appl Physiol 1999; 87: 1038–47

    PubMed  CAS  Google Scholar 

  64. Roquet A, Dahlén B, Kumlin M, et al. Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late-phase airway obstruction in asthmatics. Am J Respir Crit Care Med 1997; 155: 1856–63

    PubMed  CAS  Google Scholar 

  65. Thomson L, Blaylock MG, Sexton DW, et al. Cetirizine and levocetirizine inhibit eotaxin-induced eosinophil transendothelial migration through human dermal or lung microvascular endothelial cells. Clin Exp Allergy 2002; 32: 1187–92

    PubMed  CAS  Article  Google Scholar 

  66. Molet S, Gosset P, Lassaller P, et al. Inhibitory activity of loratadine and descarboxyethoxyloratadine on human histamine-induced activation of endothelial cells. Clin Exp Allergy 1997; 27: 1167–74

    PubMed  CAS  Article  Google Scholar 

  67. Shimuzu T, Nishihara J, Watanabe H, et al. Cetirizine, an H1-receptor antagonist, suppresses the expression of macrophage migration inhibitory factor: its potential anti-inflammatory action. Clin Exp Allergy 2004; 34: 103–9

    Article  Google Scholar 

  68. Wood-Baker R, Lau L, Howarth PH. Histamine and the nasal vasculature: the influence of H1 and H2-histamine receptor antagonism. Clin Otolaryngol 1996; 21: 348–52

    PubMed  CAS  Article  Google Scholar 

  69. Wang DY, Hanotte F, De Vos C, et al. Effect of cetirizine, levocetirizine, and dextrocetirizine on histamine-induced nasal response in healthy adult volunteers. Allergy 2001; 56: 339–43

    PubMed  CAS  Article  Google Scholar 

  70. Austin CE, Dear JW, Neighbour H, et al. The contribution of histamine to the action of bradykinin in the human nasal airway. Immunopharmacology 1996; 34: 181–9

    PubMed  CAS  Article  Google Scholar 

  71. Ghosh SK, Rafferty P, De Vos C, et al. Effect of cetirizine, a potent H1 antagonist, on platelet activating factor induced bronchoconstriction in asthma. Clin Exp Allergy 1993; 23: 524–7

    PubMed  CAS  Article  Google Scholar 

  72. Dobashi K, Iizuka K, Houjou S, et al. Effect of cetirizine on antigen-induced tracheal contraction of passively sensitized guinea pigs. Ann Allergy Asthma Immunol 1996; 77: 310–8

    PubMed  CAS  Article  Google Scholar 

  73. Song P, Crimi E, Milanese M, et al. Anti-inflammatory agents and allergy-induced β2-receptor dysfunction in isolated human bronchi. Am J Respir Crit Care Med 1998; 158: 1809–14

    PubMed  CAS  Google Scholar 

  74. McLeod RL, Mingo G, O’Reilly S, et al. Antitussive action of antihistamines is independent of sedative and ventilation activity in the guinea pig. Pharmacology 1998; 57: 57–64

    PubMed  CAS  Article  Google Scholar 

  75. Llupià J, Gras J, Llenas J. Comparative antiallergic effects of second-generation H1-antihistamines ebastine, cetirizine and loratadine in preclinical models. Arzneimittelforschung 2003; 53: 93–7

    PubMed  Google Scholar 

  76. Horak F, Stübner UP, Zieglmayer R, et al. Comparison of the effects of desloratadine 5mg daily and placebo on nasal airflow and seasonal allergy rhinitis symptoms induced by grass pollen exposure. Allergy 2003; 58: 481–5

    PubMed  CAS  Article  Google Scholar 

  77. Horak F, Stübner UP, Zieglmayer R, et al. Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit. J Allergy Clin Immunol 2002; 109: 956–61

    PubMed  CAS  Article  Google Scholar 

  78. Kreutner W, Hey JA, Anthes J, et al. Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist. 1st communication: receptor selectivity, antihistaminic activity, and antiallergenic effects. Arzneimittelforschung 2000; 50: 345–52

    CAS  Google Scholar 

  79. Greiff L, Persson CGA, Andersson M. Desloratadine reduces allergen challenge-induced mucinous secretion and plasma exudation in allergic rhinitis. Ann Allergy Asthma Immunol 2002; 89: 413–8

    PubMed  CAS  Article  Google Scholar 

  80. Bryce PJ, Geha R, Oettgen HC. Desloratadine inhibits allergen-induced airway inflammation and bronchial hyperresponsiveness and alters T-cell responses in murine models of asthma. J Allergy Clin Immunol 2003; 112: 149–58

    PubMed  CAS  Article  Google Scholar 

  81. Lee DKC, Bates CE, Currie GP, et al. Comparative in vivo bioactivity of modern H1-antihistamines on AMP challenge in atopic asthma. J Allergy Clin Immunol 2003; 111: 337–41

    PubMed  CAS  Article  Google Scholar 

  82. Brannan JD, Anderson SD, Gomes K, et al. Fexofenadine decreases sensitivity to and montelukast improves recovery from inhaled mannitol. Am J Respir Crit Care Med 2001; 163: 1420–5

    PubMed  CAS  Google Scholar 

  83. Gelfand EW, Cui Z-H, Takeda K, et al. Effects of fexofenadine on T-cell function in a murine model of allergen-induced airway inflammation and hyperresponsiveness. J Allergy Clin Immunol 2003; 112 (4 Suppl.): 89–95

    Article  Google Scholar 

  84. Gelfand EW, Cui Z-H, Takeda K, et al. Fexofenadine modulates T-cell function preventing allergen-induced airway inflammation and hyperresponsiveness. J Allergy Clin Immunol 2002; 110:85–95

    PubMed  CAS  Article  Google Scholar 

  85. Amsellem C, Gormand F, Hosni R, et al. Antihistamines and production of granulocyte-macrophage colony-stimulating factor and interleukin-8 by human bronchial epithelial cells in vitro: evaluation of the effects of loratadine and cetirizine. Gen Pharmacol 1996; 27: 269–72

    PubMed  CAS  Article  Google Scholar 

  86. Tasaka K, Kamei C, Akagi M, et al. Effect of loratadine on immediate and delayed type hypersensitivity reactions. Arzneimittelforschung 1995; 45: 796–8

    PubMed  CAS  Google Scholar 

  87. Karppinen A, Rantala I, Vaalasti A. Effect of cetirizine on the inflammatory cells in mosquito bites. Clin Exp Allergy 1996; 26: 703–9

    PubMed  CAS  Article  Google Scholar 

  88. Yakuo I, Yabuuchi M, Ito T. Preclinical comparison of ebastine and other second generation H1-antihistamines. Pharmacol Toxicol 2001; 89: 171–6

    PubMed  CAS  Article  Google Scholar 

  89. Charlesworth EN, Kagey-Sobotka A, Norman PS, et al. Effect of cetirizine on mast cell-mediator release and cellular traffic during the cutaneous late-phase reaction. J Allergy Clin Immunol 1989; 83: 905–12

    PubMed  CAS  Article  Google Scholar 

  90. Charlesworth EN, Massey WA, Kagey-Sobotka A, et al. Effect of H1 receptor blockade on the early and late response to cutaneous allergen challenge. J Pharmacol Exp Ther 1992; 263: 964–70

    Google Scholar 

  91. Lippert U, Hoer A, Möller A, et al. Role of antigen-induced cytokine release in atopic pruritus. Int Arch Allergy Immunol 1998; 116: 36–9

    PubMed  CAS  Article  Google Scholar 

  92. Fadel R, Herpin-Richard N, Rihoux J-P, et al. Inhibitory effect of cetirizine 2HCl on eosinophil migration in vivo. Clin Allergy 1987; 17: 373–9

    PubMed  CAS  Article  Google Scholar 

  93. Nielsen PN, Skov PS, Poulsen LK, et al. Cetirizine inhibits skin reactions but not mediator release in immediate and developing late-phase allergic cutaneous reactions: a double-blind, placebo-controlled study. Clin Exp Allergy 2001; 31: 1378–84

    PubMed  CAS  Article  Google Scholar 

  94. Fadel R, David B, Herpin-Richard N, et al. In vivo effects of cetirizine on cutaneous reactivity and eosinophil migration induced by platelet-activating factor (PAF-acether) in man. J Allergy Clin Immunol 1990; 86: 314–20

    PubMed  CAS  Article  Google Scholar 

  95. Rihoux J-P, Fadel R, Juhlin L. Platelet-activating factor-induced immediate and late cutaneous reactions. Int Arch Allergy Immunol 1991; 94: 299–300

    CAS  Article  Google Scholar 

  96. Inagaki N, Sakurai T, Abe T, et al. Characterization of antihistamines using biphasic cutaneous reaction in BALB/c mice. Life Sci 1998; 63: 145–50

    Article  Google Scholar 

  97. Weidner C, Klede M, Rukwied R, et al. Acute effects of substance P and calcitonin gene-related peptide in human skin: a microdialysis study. J Invest Dermatol 2000; 115: 1015–20

    PubMed  CAS  Article  Google Scholar 

  98. Albanesi C, Pastore S, Fanales-Belasio E, et al. Cetirizine and hydrocortisone differentially regulate ICAM-1 expression and chemokine release in cultured human keratinocytes. Clin Exp Dermatol 1998; 28: 101–9

    CAS  Google Scholar 

  99. Caproni M, Palleschi GM, Falcos D, et al. Pharmacologic modulation by cetirizine of some adhesion molecules expression in psoriatic skin lesions. Int J Dermatol 1995; 14: 510–3

    Article  Google Scholar 

  100. Pestelli E, Floriani I, Fabri P, et al. Cetirizine modulates adhesion molecule expression in a double-blind controlled study conducted in psoriatic patients. Int J Tissue React 2003; 25: 1–8

    PubMed  CAS  Google Scholar 

  101. Vena GA, Cassano N, Filieri M, et al. Fexofenadine in chronic idiopathic urticaria: a clinical and immunohistochemical evaluation. Int J Immunopathol Pharmacol 2002; 15: 217–24

    PubMed  CAS  Google Scholar 

  102. Friedmann PS. Assessment of urticaria and angio-oedema. Clin Exp Allergy 1999; 29 Suppl. 3: 109–12

    PubMed  Article  Google Scholar 

  103. Monroe EW, Daly AF, Shalhoub RF. Appraisal of the validity of histamine-induced wheal and flare to predict the clinical efficacy of antihistamines. J Allergy Clin Immunol 1997; 99(2): 798–806

    Article  Google Scholar 

  104. Purohit A, Melac M, Pauli G, et al. Comparative activity of cetirizine and desloratadine on histamine-induced wheal-and-flare responses during 24 hours. Ann Allergy Asthma Immunol 2004; 92: 635–40

    PubMed  CAS  Article  Google Scholar 

  105. Simons FER, Semus MJ, Goritz SS, et al. H1-antihistaminic activity of cetirizine and fexofenadine in allergic children. Pediatr Allergy Immunol 2003; 14: 207–11

    PubMed  Article  Google Scholar 

  106. Ramboer I, Bumbacea R, Lazarescu D, et al. Cetirizine and loratadine: a comparison using the ED50 in skin reactions. J Int Med Res 2000; 28: 69–77

    PubMed  CAS  Google Scholar 

  107. Gispert J, Antonijoan R, Barbanoj M, et al. Efficacy of ebastine, cetirizine, and loratadine in histamine cutaneous challenges. Ann Allergy Asthma Immunol 2002; 89: 259–64

    PubMed  CAS  Article  Google Scholar 

  108. Grant JA, Danielson L, Rihoux J-P, et al. A double-blind, single-dose crossover comparison of cetirizine, ebastine, epinastine, fexofenadine, terfenadine, and loratadine versus placebo: suppression of wheal and flare response for 24h in healthy male subjects. Allergy 1999; 54: 700–7

    PubMed  CAS  Article  Google Scholar 

  109. van Steekelenburg J, Clement PAR, Beel MHL. Comparison of five new antihistamines (H1-receptor antagonists) in patients with allergic rhinitis using nasal provocation studies and skin tests. Allergy 2002; 57: 346–50

    PubMed  Article  Google Scholar 

  110. Rukwied R, Lischetzki G, McGlone F, et al. Mast cell mediators other than histamine induce pruritus in atopic dermatitis patients: a dermal microdialysis study. Br J Dermatol 2000; 142: 1114–20

    PubMed  CAS  Article  Google Scholar 

  111. de la Cuadra J, Teruel M, Teixido P, et al. Assessment of the wheal size and skin blood flow of the erythema induced by histamine and its modification with cetirizine and ebastine: a crossover, double-blind study. Dermatology 1994; 188: 131–4

    PubMed  Article  Google Scholar 

  112. Frossard N, Melac M, Benabdesselam O, et al. Consistency of the efficacy of cetirizine and ebastine on skin reactivity. Ann Allergy Asthma Immunol 1998; 80: 61–5

    PubMed  CAS  Article  Google Scholar 

  113. Purohit A, Duvernelle C, Melac M, et al. Consistency and efficacy of cetirizine (10mg) versus ebastine (20mg) at 4h on skin reactivity. Eur J Clin Pharmacol 1999; 55: 589–92

    PubMed  CAS  Article  Google Scholar 

  114. van Neste D, Leroy D-T, de Brouwer B, et al. Histamine-induced skin reactions using iontophoresis and H1-blockade. Inflamm Res 1996; 45 Suppl. 1: 48–9

    Google Scholar 

  115. Devalia JL, De Vos C, Hanotte F, et al. A randomized, double-blind, crossover comparison among cetirizine, levocetirizine and UCB 28557 on histamine-induced cutaneous responses in healthy adult volunteers. Allergy 2001; 56: 50–7

    PubMed  CAS  Article  Google Scholar 

  116. Purohit A, Melac M, Pauli G, et al. Comparative activity of cetirizine and mizolastine on histamine-induced skin wheal and flare responses at 24 h. Br J Clin Pharmacol 2002; 53: 250–4

    PubMed  CAS  Article  Google Scholar 

  117. Fadel R, Ramboer I, Chatterjee N, et al. Cetirizine inhibits bradykinin-induced cutaneous wheal and flare in atopic and healthy subjects. Allergy 2000; 55: 382–5, 888–91

    PubMed  CAS  Article  Google Scholar 

  118. Grob JJ, Castelain M, Richard MA, et al. Antiinflammatory properties of cetirizine in a human contact dermatitis model: clinical evaluation of patch tests is not hampered by antihistamines. Acta Derm Venereol 1998; 78: 194–7

    PubMed  CAS  Article  Google Scholar 

  119. Atkins PC, Zweiman B, Moskovitz A, et al. Cellular inflammatory responses and mediator release during early developing late-phase allergic cutaneous inflammatory responses: effects of cetirizine. J Allergy Clin Immunol 1997; 99: 806–11

    PubMed  CAS  Article  Google Scholar 

  120. Snyman JR, Sommers DK, Gregorowski MD, et al. Effect of cetirizine, ketotifen and chlorpheniramine on the dynamics of the cutaneous hypersensitivity reaction: a comparative study. Eur J Clin Pharmacol 1992; 42: 359–62

    PubMed  CAS  Google Scholar 

  121. Zweiman B, Atkins PC, Moskovitz A, et al. Cellular inflammatory responses during immediate, developing, and established late-phase allergic cutaneous reactions: effects of cetirizine. J Allergy Clin Immunol 1997; 100: 341–7

    PubMed  CAS  Article  Google Scholar 

  122. Juhlin L, Rihoux J-P. Effect of cetirizine on cutaneous reactions to PAF, kallikrein and serum in patients with chronic urticaria. Acta Derm Venereol 1990; 70: 151–3

    PubMed  CAS  Google Scholar 

  123. Borici-Mazi R, Kouridakis S, Kontou-Fili K. Cutaneous responses to substance P and calcitonin gene-related peptide in chronic urticaria: the effect of cetirizine and dimethindene. Allergy 1999; 54: 46–56

    PubMed  CAS  Article  Google Scholar 

  124. Simons FER, Johnston L, Gu X, et al. Suppression of the early and late cutaneous allergic responses using fexofenadine and montelukast. Ann Allergy Asthma Immunol 2001; 86: 44–50

    PubMed  CAS  Article  Google Scholar 

  125. Urabe K, Nakahara T, Moroi V, et al. Mite-antigen induced immediate reactions in Atopic dermatitis are inhibited by daily administration of fexofenadine [letter]. J Dermatol 2003; 30: 847–8

    PubMed  Google Scholar 

  126. Grant JA, Riethuisen J-M, Moulaert B, et al. A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects. Ann Allergy Asthma Immunol 2002; 88: 190–7

    PubMed  CAS  Article  Google Scholar 

  127. Kaliner MA, White MV, Economides A, et al. Relative potency of fexofenadine HCl 180mg, loratadine 10mg, and placebo using a skin test model of wheal-and-flare suppression. Ann Allergy Asthma Immunol 2003; 90: 629–34

    PubMed  CAS  Article  Google Scholar 

  128. Roquet A, Raud J, Halldén G, et al. Effects of loratadine on anti-IgE-induced inflammation, histamine release, and leukocyte recruitment in skin of atopics. Allergy 1995; 50: 414–20

    PubMed  CAS  Article  Google Scholar 

  129. Bousquet J, Czarlewski W, Cougnard J, et al. Changes in skin-test reactivity do not correlate with clinical efficacy of H1-blockers in seasonal allergic rhinitis. Allergy 1998; 53: 579–85

    PubMed  CAS  Article  Google Scholar 

  130. Grant JA, Danielson L, Rihoux J-P, et al. A comparison of cetirizine, ebastine, epinastine, fexofenadine, terfenadine, and loratadine versus placebo in suppressing the cutaneous response to histamine. Int Arch Allergy Immunol 1999; 118: 339–40

    PubMed  CAS  Article  Google Scholar 

  131. Juhlin L. A comparison of the pharmacodynamics of H1-receptor antagonists as assessed by the induced wheal-and-flare model. Allergy 1995; 50: 24–30

    PubMed  CAS  Article  Google Scholar 

  132. Simons FER, Simons KJ. Clinical pharmacology of new histamine H1 receptor antagonists. Clin Pharmacokinet 1999; 36: 329–52

    PubMed  CAS  Article  Google Scholar 

  133. Baltes E, Coupez R, Giezek H, et al. Absorption and disposition of levocetirizine, the eutomer of cetirizine, administered alone or as cetirizine to healthy volunteers. Fundam Clin Pharmacol 2001; 15: 269–77

    PubMed  CAS  Article  Google Scholar 

  134. Benedetti MS, Plisnier M, Kaise J, et al. Absorption, distribution, metabolism and excretion of [14C]levocetirizine, the r enantiomer of cetirizine, in healthy volunteers. Eur J Clin Pharmacol 2001; 57: 571–82

    PubMed  CAS  Article  Google Scholar 

  135. Wood SG, John BA, Chasseaud LF, et al. The metabolism and pharmacokinetics of 14-cetirizine in humans. Ann Allergy 1987; 59 (6 Pt 2): 31–4

    PubMed  CAS  Google Scholar 

  136. Robbins DK, Castles MA, Pack DJ, et al. Dose proportionality and comparison of single and multiple dose pharmacokinetics of fexofenadine (MDL 16455) and its enantiomers in healthy male volunteers. Biopharm Drug Dispos 1998; 19: 455–63

    PubMed  CAS  Article  Google Scholar 

  137. Russell T, Stoltz M, Weir S. Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers. Clin Pharmacol Ther 1998; 64: 612–21

    PubMed  CAS  Article  Google Scholar 

  138. Affrime M, Banfield C, Gupta S, et al. Effect of race and sex on single and multiple dose pharmacokinetics of desloratadine. Clin Pharmacokinet 2002; 41 Suppl. 1: 21–8

    PubMed  CAS  Article  Google Scholar 

  139. Gupta S, Banfield C, Affrime M, et al. Desloratadine demonstrates dose proportionality in healthy adults after single doses. Clin Pharmacokinet 2002; 41 Suppl. 1: 1–6

    PubMed  CAS  Article  Google Scholar 

  140. Hilbert J, Radwanski E, Weglein R, et al. Pharmacokinetics and dose proportionality of loratadine. J Clin Pharmacol 1987; 27: 694–8

    PubMed  CAS  Google Scholar 

  141. Day JH, Briscoe M, Rafeiro E, et al. Comparative onset of action and symptom relief with cetirizine, loratadine, or placebo in an environmental exposure unit in subjects with seasonal allergic rhinitis: confirmation of a test system. Ann Asthma Allergy Immunol 2001; 87: 474–81

    CAS  Article  Google Scholar 

  142. Zhang Y-F, Chen X-Y, Zhong D-F, et al. Pharmacokinetics of loratadine and its active metabolite descarboethoxyloratadine in healthy Chinese subjects. Acta Pharmacol Sinica 2003; 24: 715–8

    CAS  Google Scholar 

  143. Radwanski E, Hilbert J, Symchowicz S, et al. Loratadine: multiple-dose pharmacokinetics. J Clin Pharmacol 1987; 27: 530–3

    PubMed  CAS  Google Scholar 

  144. Frossard N, Lacronique J, Melac M, et al. Onset of action in the nasal antihistaminic effect of cetirizine and loratadine in patients with allergic rhinitis. Allergy 1997; 52: 205–9

    PubMed  CAS  Article  Google Scholar 

  145. Petersen LJ, Church MK, Rihoux J-P, et al. Measurement of interstitial cetirizine concentrations in human skin: correlation of drug levels with inhibition of histamine-induced skin responses. Allergy 1999; 54: 607–11

    PubMed  CAS  Article  Google Scholar 

  146. Ballmer-Weber BK, Gex-Collet C, Wüthrich B. Inhibition of histamine or allergen-induced wheals by a single dose of acrivastine, fexofenadine or cetirizine. J Invest Allergol Clin Immunol 1999; 9: 351–5

    CAS  Google Scholar 

  147. Simons FER, Simons KJ. Peripheral H1-blockade effect of fexofenadine. Ann Allergy Asthma Immunol 1997; 79: 530–2

    PubMed  CAS  Article  Google Scholar 

  148. Halliday J, Briscoe MP, Welsh A, et al. Onset of action, efficacy, and safety of a single dose of fexofenadine hydrochloride for ragweed allergy using an environmental exposure unit. Ann Allergy Asthma Immunol 1997; 79: 533–40

    Article  Google Scholar 

  149. Purohit A, Duvernelle C, Melac M, et al. Twenty-four hours of activity of cetirizine and fexofenadine in the skin. Ann Allergy Asthma Immunol 2001; 86: 387–92

    PubMed  CAS  Article  Google Scholar 

  150. Day JH, Briscoe MP, Rafeiro E, et al. Randomized double-blind comparison of cetirizine and fexofenadine after pollen challenge in the environmental exposure unit: duration of effect in subjects with seasonal allergic rhinitis. Allergy Asthma Proc 2004; 25: 59–68

    PubMed  CAS  Google Scholar 

  151. Horak F, Stübner UP, Zieglmayer R, et al. Onset and duration of action of desloratadine after controlled pollen challenges in patients with seasonal allergic rhinitis [abstract no. 1000]. Allergy 2000; 55 Suppl. 63: 278

    Google Scholar 

  152. Purohit A, Melac M, Pauli G, et al. Twenty-four-hour activity and consistency of activity of levocetirizine and desloratadine in the skin. Br J Clin Pharmacol 2003; 56: 388–94

    PubMed  CAS  Article  Google Scholar 

  153. Day JH, Briscoe MP, Rafeiro E, et al. Comparative clinical efficacy, onset and duration of action of levocetirizine and desloratadine for symptoms of seasonal allergic rhinitis in subjects evaluated in the Environmental Exposure Units (EEU). Int J Clin Pract 2004; 59: 109–18

    Article  Google Scholar 

  154. Lippert C, Ling J, Brown P, et al. Mass balance and pharmacokinetics of MDL 16,455A in healthy male volunteers [abstract no. 8253]. Pharm Res 1995; 12 Suppl.: 390

    Google Scholar 

  155. Clarinex® (desloratadine) tablets: package insert. Kenilworth (NJ): Schering Corporation, 2003

  156. Zuberbier T, Henz BM. Use of cetirizine in dermatologic disorders. Ann Allergy Asthma Immunol 1999; 83: 476–80

    PubMed  CAS  Article  Google Scholar 

  157. Stoltz M, Arumugham T, Lippert C, et al. Effect of food on the bioavailability of fexofenadine hydrochloride (MDL 16455A). Biopharm Drug Dispos 1997; 18: 645–8

    PubMed  CAS  Article  Google Scholar 

  158. Gupta S, Banfield C, Marbury T, et al. Oral bioavailability of desloratadine is unaffected by food. Clin Pharmacokinet 2002; 41 Suppl. 1: 7–12

    PubMed  CAS  Article  Google Scholar 

  159. Nomier AA, Mojaverian P, Kosoglou T, et al. Influence of food on the oral bioavailability of loratadine and pseudoephedrine from extended-release tablets in healthy volunteers. J Clin Pharmacol 1996; 36: 923–30

    Google Scholar 

  160. Urien S, Tillement J-P, Ganem B, et al. A pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effects of cetirizine. Int J Clin Pharmacol Ther 1999; 37: 499–502

    PubMed  CAS  Google Scholar 

  161. Tillement J-P. The advantages for an H1 antihistamine of a low volume of distribution. Allergy 2000; 55 Suppl. 60: 17–21

    PubMed  Article  Google Scholar 

  162. González MA, Estes KS. Pharmacokinetic overview of oral second-generation H1 antihistamines. Int J Clin Pharmacol Ther 1998; 36: 292–300

    PubMed  Google Scholar 

  163. Desager J-P, Horsmans Y. Pharmacokinetic-pharmacodynamic relationships of H1-antihistamines. Clin Pharmacokinet 1995; 28: 419–32

    PubMed  CAS  Article  Google Scholar 

  164. Nicolas J-M. The metabolic profile of second-generation antihistamines. Allergy 2000; 55 Suppl. 60: 46–52

    PubMed  Article  Google Scholar 

  165. Kosoglou T, Salfi M, Lim JM, et al. Evaluation of the pharmacokinetics and electrocardiographic pharmacodynamics of loratadine with concomitant administration of ketoconazole or cimetidine. Br J Clin Pharmacol 2000; 50: 581–9

    PubMed  CAS  Article  Google Scholar 

  166. Yumibe N, Huie K, Chen K-J, et al. Identification of human liver cytochrome P-450 enzymes that metabolize the nonsedating antihistamine loratadine: formation of descarboethoxyloratadine by CYP 3A4 and CYP 2D 6. Biochem Pharmacol 1996; 51: 165–72

    PubMed  CAS  Article  Google Scholar 

  167. Nicolas J-M, Whomsley R, Collart P, et al. In vitro inhibition of human liver drug metabolizing enzymes by second generation antihistamines. Chem Biol Interact 1999; 123: 63–79

    PubMed  CAS  Article  Google Scholar 

  168. Kosoglou T, Radwanski E, Batra VK, et al. Pharmacokinetics of loratadine and pseudoephedrine following single and multiple doses of onceversus twice-daily combination tablet formulations in healthy adult males. Clin Ther 1997; 19: 1002–12

    PubMed  CAS  Article  Google Scholar 

  169. Padhi D, Banfield C, Gupta S, et al. Multiple-dose pharmacokinetics, safety, and tolerance of desloratadine in healthy volunteers [abstract no. 1124]. J Allergy Clin Immunol 2000; 104 Suppl. 1: 385

    Article  Google Scholar 

  170. Simons FER, Murray HE, Simons KD. Quantitaten of H1-receptor antagonists in skin and serum. J Allergy Clin Immunol 1995; 95: 759–64

    PubMed  CAS  Article  Google Scholar 

  171. Rivest J, Despontin K, Ghys L, et al. Pharmacological modulation by cetirizine and ebastine of the cutaneous reactivity to histamine. Dermatologica 1991; 383: 208–11

    Article  Google Scholar 

  172. Simons FE, Johnston L, Simons KJ. Clinical pharmacology of H1-receptor antagonists cetirizine and loratadine in children. Pediatr Allergy Immunol 2000; 11: 116–9

    PubMed  CAS  Article  Google Scholar 

  173. Frossard N, Benabdesselam O, Melac M, et al. Nasal effect of cetirizine at 24 hours in patients with allergic rhinitis. Am J Ther 1998; 5: 307–11

    PubMed  CAS  Article  Google Scholar 

  174. Meltzer EO, Weiler JM, Widlitz MD. Comparative outdoor study of the efficacy, onset and duration of action, and safety of cetirizine, loratadine, and placebo for seasonal allergic rhinitis. J Allergy Clin Immunol 1996; 97: 617–6

    PubMed  CAS  Article  Google Scholar 

  175. Testa B, Pagliara A, Carrupt PA. The molecular behaviour of cetirizine. Clin Exp Allergy 1997; 27 Suppl. 2: 13–8

    PubMed  CAS  Article  Google Scholar 

  176. van Balen GP, Caron G, Ermondi G, et al. Lipophilicity behaviour of the zwitterionic antihistamine cetirizine in phosphatidylcholine liposomes/water systems. Pharm Res 2001; 18: 694–701

    Article  Google Scholar 

  177. Pagliara A, Testa B, Carrupt P-A, et al. Molecular properties and pharmacokinetic behavior of cetirizine, a zwitterionic H1-receptor antagonist. J Med Chem 1998; 41: 853–63

    PubMed  CAS  Article  Google Scholar 

  178. Simons FER, Sussman GL, Simons KJ. Effect of the H2-antagonist cimetidine on the pharmacokinetics and pharmacodynamics of the H1-antagonists hydroxyzine and cetirizine in patients with chronic urticaria. J Allergy Clin Immunol 1995; 95: 685–93

    PubMed  CAS  Article  Google Scholar 

  179. Ambudkar SV, Dey S, Hrycyna CA, et al. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999; 39: 361–98

    PubMed  CAS  Article  Google Scholar 

  180. Loo TW, Clarke DM. Determining the structure and mechanism of the human multidrug resistance P-glycoprotein using cysteine-scanning mutagenesis and thiol-modification techniques. Biochim Biophys Acta 1999; 1461: 315–25

    PubMed  CAS  Article  Google Scholar 

  181. Cvetkovic M, Leake B, Fromm MF, et al. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 1999; 27: 866–71

    PubMed  CAS  Google Scholar 

  182. Hansten PD, Levy RH. Role of P-glycoprotein and organic anion transporting polypeptides in drug absorption and distribution: focus on H1-receptor antagonists. Clin Drug Invest 2001; 21: 587–96

    CAS  Article  Google Scholar 

  183. Nozawa T, Imai K, Nezu J-I, et al. Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther 2004; 308: 438–45

    PubMed  Article  CAS  Google Scholar 

  184. Drescher S, Schaeffeler E, Hitzl M, et al. MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br J Clin Pharmacol 2002; 53: 526–34

    PubMed  CAS  Article  Google Scholar 

  185. Perloff MD, von Moltke LL, Greenblatt DJ. Fexofenadine transport in Caco-2 cells: inhibition with verapamil and ritonavir. J Clin Pharmacol 2002; 42: 1269–74

    PubMed  CAS  Article  Google Scholar 

  186. Putnam WS, Ramanathan S, Pan L, et al. Functional characterization of monocarboxylic acid, large neutral amino acid, bile acid and peptide transporters, and P-glycoprotein in MDCK and Caco-2 cells. J Pharm Sci 2002; 91: 2622–35

    PubMed  CAS  Article  Google Scholar 

  187. Chiou WL, Chung TC, Ma C. A comprehensive account on the role of efflux transporters in the gastrointestinal absorption of 13 commonly used substrate drugs in humans. Int J Clin Pharmacol Ther 2001; 39: 93–101

    PubMed  CAS  Google Scholar 

  188. Dresser GK, Bailey DG, Leake BF, et al. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther 2002; 71: 11–20

    PubMed  CAS  Article  Google Scholar 

  189. Tian R, Koyabu N, Takanaga H, et al. Effects of grapefruit juice and orange juice on the intestinal efflux of P-glycoprotein substrates. Pharm Res 2002; 19: 802–9

    PubMed  CAS  Article  Google Scholar 

  190. Paakkari I. Cardiotoxicity of new antihistamines and cisapride. Toxicol Lett 2002; 127: 279–84

    PubMed  CAS  Article  Google Scholar 

  191. Soldner A, Cristians U, Susanto M, et al. Grapefruit juice activates P-glycoprotein-mediated drug transport. Pharm Res 1999; 16: 478–85

    PubMed  CAS  Article  Google Scholar 

  192. Hamman MA, Bruce MA, Hachner-Daniels BD, et al. The effect of rifampin administration on the disposition of fexofenadine. Clin Pharmacol Ther 2001; 69: 114–21

    PubMed  CAS  Article  Google Scholar 

  193. Tashiro M, Mochizuki H, Iwabuchi K, et al. Roles of histamine in regulation and cognition: functional neuroimaging of histamine H1 receptors in human brain. Life Sci 2002; 72: 409–14

    PubMed  CAS  Article  Google Scholar 

  194. Cheung BS, Heskin R, Hofer KD. Failure of cetirizine and fexofenadine to prevent motion sickness. Ann Pharmacother 2003; 37: 173–7

    PubMed  CAS  Article  Google Scholar 

  195. de Boer AG, van der Sandt ICJ, Gaillard PJ. The role of drug transporters at the blood-brain barrier. Annu Rev Pharmacol Toxicol 2003; 43: 629–56

    PubMed  Article  CAS  Google Scholar 

  196. Chen C, Hanson E, Watson JW, et al. P-glycoprotein limits the brain penetration of nonsedating but not sedating H1 antagonists. Drug Metab Dispos 2003; 31: 312–8

    PubMed  CAS  Article  Google Scholar 

  197. Wang E-J, Casciano CN, Clement RP, et al. Evaluation of the interaction of loratadine and desloratadine with P-glycoprotein. Drug Metab Dispos 2001; 29: 1080–3

    PubMed  CAS  Google Scholar 

  198. Rolli JW, Baughman TM, Humphreys JE, et al. P-glycoprotein influences the brain concentrations of cetirizine (Zyrtec®), a second-generation non-sedating antihistamine. J Pharm Sci 2003; 92: 2082–9

    Article  CAS  Google Scholar 

  199. Doan KMM, Wring SA, Shampine LJ, et al. Steady-state brain concentrations of antihistamines in rats: interplay of membrane permeability, P-glycoprotein efflux and plasma protein binding. Pharmacology 2004; 72: 92–8

    CAS  Article  Google Scholar 

  200. Matzke GR, Yeh J, Awni QM, et al. Pharmacokinetics of cetirizine in the elderly and patients with renal insufficiency. Ann Allergy 1987; 59 (6 Pt 2): 25–9

    PubMed  CAS  Google Scholar 

  201. Affrime M, Gupta S, Banfield C, et al. A pharmacokinetic profile of desloratadine in healthy adults, including elderly. Clin Pharmacokinet 2002; 41 Suppl. 1: 13–9

    PubMed  CAS  Article  Google Scholar 

  202. Hilbert J, Moritzen V, Parks A, et al. The pharmacokinetics of loratadine in normal geriatric volunteers. J Int Med Res 1988; 16: 50–60

    PubMed  CAS  Google Scholar 

  203. Desager JP, Dab I, Horsmans Y, et al. A pharmacokinetic evaluation of the second-generation H1-receptor antagonist cetirizine in very young children. Clin Pharmacol Ther 1993; 53: 431–5

    PubMed  CAS  Article  Google Scholar 

  204. Watson WTA, Simons KJ, Chen XY, et al. Cetirizine: a pharmacokinetic and pharmacodynamic evaluation in children with seasonal allergic rhinitis. J Allergy Clin Immunol 1989; 84: 457–64

    PubMed  CAS  Article  Google Scholar 

  205. Simons FER, Bergman JN, Watson WTA, et al. The clinical pharmacology of fexofenadine in children. J Allergy Clin Immunol 1996; 98: 1062–4

    PubMed  CAS  Article  Google Scholar 

  206. Salmun LM, Herron JM, Banfield C, et al. The pharmacokinetics, electrocardiographic effects, and tolerability of loratadine syrup in children aged 2 to 5 years. Clin Ther 2000; 22: 613–21

    PubMed  CAS  Article  Google Scholar 

  207. Spičák V, Dab I, Hulhoven R, et al. Pharmacokinetics and pharmacodynamics of cetirizine in infants and toddlers. Clin Pharmacol Ther 1997; 61: 325–30

    PubMed  Article  Google Scholar 

  208. Horsmans Y, Desager JP, Hulhoven R, et al. Single-dose pharmacokinetics of cetirizine in patients with chronic liver disease. J Clin Pharmacol 1993; 33: 929–32

    PubMed  CAS  Google Scholar 

  209. Simons FER, Watson WTA, Minuk GY, et al. Cetirizine pharmacokinetics and pharmacodynamics in primary biliary cirrhosis. J Clin Pharmacol 1993; 33: 949–54

    PubMed  CAS  Google Scholar 

  210. Lippert CL, Rao N, Eller M, et al. Pharmacokinetics of fexofenadine in liver diseased patients [abstract no. 8153]. Pharm Res 1996; 13 Suppl.: 431

    Google Scholar 

  211. Noiri E, Ozawa H, Fujita T, et al. Pharmacokinetics of cetirizine in chronic hemodialysis patients: multiple-dose study. Nephron 2001; 89: 101–4

    PubMed  CAS  Article  Google Scholar 

  212. Awni WM, Yeh J, Halstenson CE, et al. Effect of haemodialysis on the pharmacokinetics of cetirizine. Eur J Clin Pharmacol 1990; 38: 67–9

    PubMed  CAS  Article  Google Scholar 

  213. Robbins DK, Horton MW, Swan SK, et al. Pharmacokinetics of fexofenadine in patients with varying degrees of renal impairment [abstract no. 8154]. Pharm Res 1996; 13 Suppl.: 431

    Google Scholar 

  214. Matzke GR, Halstenson CE, Opsahl JA, et al. Pharmacokinetics of loratadine in patients with renal insufficiency. J Clin Pharmacol 1990; 30: 364–71

    PubMed  CAS  Google Scholar 

  215. Nathan RA, Meltzer EO, Selner JC, et al. Prevalence of allergic rhinitis in the United States. J Allergy Clin Immunol 1997; 99 Suppl. 6 Pt 2: 808–14

    Article  Google Scholar 

  216. Meltzer EO, Nathan RA, Selner JC, et al. Quality of life and rhinitic symptoms: results of a nationwide survey with the SF-36 and RQLQ questionnaires. J Allergy Clin Immunol 1997; 99 Suppl.: 815–9

    Article  Google Scholar 

  217. Fireman P. Treatment strategies designed to minimize medical complications of allergic rhinitis. Am J Rhinol 1997; 11: 95–102

    PubMed  CAS  Article  Google Scholar 

  218. Bosquet J, van Cauwenberge P, Khaltaev N, et al. Allergic rhinitis and its impact on asthma: ARIA Workshop Report. J Allergy Clin Immunol 2001; 108 (5 Suppl.): 147–334

    Article  Google Scholar 

  219. Corren J, Manning BE, Thompson SE, et al. Rhinitis therapy and the prevention of hospital care for asthma: a case-control study. J Allergy Clin Immunol 2004; 113: 415–9

    PubMed  Article  Google Scholar 

  220. Storms W, Meltzer EO, Nathan RA, et al. The economic impact of allergic rhinitis. J Allergy Clin Immunol 1997; 99 Suppl. 6 Pt 2: 820–4

    Article  Google Scholar 

  221. Rosenwasser LJ. Treatment of allergic rhinitis. Am J Med 2002; 113 Suppl. 9A: 17–24

    Article  Google Scholar 

  222. Scadding GK. Clinical assessment of antihistamines in rhinitis. Clin Exp Allergy 1999; 29 Suppl. 3: 77–81

    PubMed  CAS  Article  Google Scholar 

  223. Berger WE, Fineman SM, Lieberman P, et al. Double-blind trials of azelastine nasal spray monotherapy versus combination therapy with loratadine tablets and beclomethasone nasal spray in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1999; 82: 535–41

    PubMed  CAS  Article  Google Scholar 

  224. Jordana G, Dolovich J, Briscoe MP, et al. Intranasal fluticasone propionate versus loratadine n the treatment of adolescent patients with seasonal allergic rhinitis. J Allergy Clin Immunol 1996; 97: 588–95

    PubMed  CAS  Article  Google Scholar 

  225. Ratner PH, van Bavel JH, Martin BG, et al. A comparison of the efficacy of fluticasone propionate aqueous nasal spray and loratadine, alone and in combination, for the treatment of seasonal allergic rhinitis. J Fam Pract 1998; 47: 1118–25

    Google Scholar 

  226. Foresi A. A comparison of the clinical efficacy and safety of intranasal fluticasone propionate and antihistamines in the treatment of rhinitis. Allergy 2000; 62 Suppl. 62: 12–4

    Article  Google Scholar 

  227. Géhanno P, Deslougeres J-L. Fluticasone propionate aqueous nasal spray compared with oral loratadine in patients with seasonal allergic rhinitis. Allergy 1997; 52: 445–50

    PubMed  Article  Google Scholar 

  228. Kaszuba SM, Baroody FM, de Tineo M, et al. Superiority of an intranasal corticosteroid compared with an oral antihistamine in the as-needed treatment of seasonal allergic rhinitis. Arch Intern Med 2001; 161: 2581–7

    PubMed  CAS  Article  Google Scholar 

  229. Wilson A, Dempsey OJ, Sims EJ, et al. Evaluation of treatment response in patients with seasonal allergic rhinitis using domiciliary nasal peak inspiratory flow. Clin Exp Allergy 2000; 30: 833–8

    PubMed  CAS  Article  Google Scholar 

  230. Wilson AM, Orr LC, Sims EJ, et al. Antiasthmatic effects of mediator blockade versus topical corticosteroids in allergic rhinitis and asthma. Am J Respir Crit Care Med 2000; 162: 1297–301

    PubMed  CAS  Google Scholar 

  231. Wilson AM, Orr LC, Sims EJ, et al. Effects of monotherapy with intra-nasal corticosteroid or combined oral histamine and leukotriene receptor antagonists in seasonal allergic rhinitis. Clin Exp Allergy 2001; 31: 61–8

    PubMed  CAS  Google Scholar 

  232. Wilson AM, Sims EJ, Orr LC, et al. Effects of topical corticosteroid and combined mediator blockade on domiciliary and laboratory measurements of nasal function in seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2001; 87: 344–9

    PubMed  CAS  Article  Google Scholar 

  233. Dykewicz MS, Fineman S, Skoner DP, et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 1998; 81: 478–518

    PubMed  CAS  Article  Google Scholar 

  234. Galant SP, Wilkinson R. Clinical prescribing of allergic rhinitis medication in the preschool and young school-age child: what are the options? Biodrugs 2001; 15: 453–63

    PubMed  CAS  Article  Google Scholar 

  235. Nash DB, Sullivan SD, Mackowiak J. Optimizing quality and cost effectiveness in treating allergic rhinitis in a managed care setting. Am J Manag Care 2000; 6 Suppl. 1: 3–15

    Google Scholar 

  236. Nielsen LP, Mygind N, Dahl R. Intranasal corticosteroids for allergic rhinitis: superior relief? Drugs 2001; 61: 1563–79

    PubMed  CAS  Article  Google Scholar 

  237. Weiner JM, Abramson MJ, Puy RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. BMJ 1998; 317: 1624–9

    PubMed  CAS  Article  Google Scholar 

  238. Wilson AM, O’Byrne PM, Parameswaran K. Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis. Am J Med 2004; 116: 338–44

    PubMed  CAS  Article  Google Scholar 

  239. Nayak AS, Philip G, Lu S, et al. Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall. Ann Allergy Asthma Immunol 2002; 88: 592–600

    PubMed  CAS  Article  Google Scholar 

  240. Pullerits T, Praks L, Ristioja V, et al. Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 2002; 109: 949–55

    PubMed  CAS  Article  Google Scholar 

  241. Topuz B, Ögmen GG. Montelukast as an adjuvant to mainstay therapies in patients with seasonal allergic rhinitis. Clin Exp Allergy 2003; 33: 823–6

    PubMed  CAS  Article  Google Scholar 

  242. van Adelsberg J, Philip G, LaForce CF, et al. Randomized controlled trial of evaluating the clinical benefit of montelukast for treating spring seasonal allergic rhinitis. J Allergy Clin Immunol 2003; 90: 214–22

    Google Scholar 

  243. Wilson AM, Orr LC, Coutie WJR, et al. A comparison of once daily fexofenadine versus the combination of montelukast plus loratadine on domiciliary nasal peak flow and symptoms in seasonal allergic rhinitis. Clin Exp Allergy 2002; 32: 126–32

    PubMed  CAS  Article  Google Scholar 

  244. McNeely W, Wiseman LR. Intranasal azelastine: a review of its efficacy in the management of allergic rhinitis. Drugs 1998; 56: 91–114

    PubMed  CAS  Article  Google Scholar 

  245. Trigg CJ, Davies RJ. Local antihistamines. Clin Exp Allergy 1996; 26: 1108–11

    PubMed  CAS  Article  Google Scholar 

  246. Howarth PH. Assessment of antihistamine efficacy and potency. Clin Exp Allergy 1999; 29 Suppl. 3: 87–97

    PubMed  CAS  Article  Google Scholar 

  247. Blaiss MS. Quality of life in allergic rhinitis. Ann Allergy Asthma Immunol 1999; 83: 449–54

    PubMed  CAS  Article  Google Scholar 

  248. Baiardini I, Pasquali M, Giardini A, et al. Rhinasthma: a new specific QoL questionnaire for patients with rhinitis and asthma. Allergy 2003; 58: 289–94

    PubMed  CAS  Article  Google Scholar 

  249. Juniper EF, Thompson AK, Ferrie PJ, et al. Development and validation of the Mini Rhinoconjunctivitis Quality of Life Questionnaire. Clin Exp Allergy 2000; 30: 132–40

    PubMed  CAS  Article  Google Scholar 

  250. Juniper EF, Thompson AK, Ferrie PJ, et al. Validation of the standardized version of the Rhinoconjunctivitis Quality of Life Questionnaire. J Allergy Clin Immunol 1999; 104: 364–9

    PubMed  CAS  Article  Google Scholar 

  251. Ciprandi G, Passalacqua G, Mincarini M, et al. Continuous versus on demand treatment with cetirizine for allergic rhinitis. Ann Allergy Asthma Immunol 1997; 79: 507–11

    PubMed  CAS  Article  Google Scholar 

  252. Ciprandi G, Tosca M, Ricca V, et al. Cetirizine treatment of rhinitis in children with pollen allergy: evidence of its antiallergic activity. Clin Exp Allergy 1997; 27: 1160–6

    PubMed  CAS  Article  Google Scholar 

  253. Pearlman DS, Lumry WR, Winder JA, et al. Once-daily cetirizine effective in the treatment of seasonal allergic rhinitis in children aged 6 to 11 years: a randomized, double-blind, placebo-controlled study. Clin Pediatr 1997; 36: 209–15

    CAS  Article  Google Scholar 

  254. Sabbah A, Daele J, Wade AG, et al. Comparison of the efficacy, safety, and onset of action of mizolastine, cetirizine, and placebo in the management of seasonal allergic rhinoconjunctivitis. Ann Allergy Asthma Immunol 1999; 83: 319–25

    PubMed  CAS  Article  Google Scholar 

  255. Murray JJ, Nathan RA, Bronsky EA, et al. Comprehensive evaluation of cetirizine in the management of seasonal allergic rhinitis: impact on symptoms, quality of life, productivity, and activity impairment. Allergy Asthma Proc 2002; 23: 391–8

    PubMed  CAS  Google Scholar 

  256. Noonan MJ, Raphael GD, Nayak A, et al. The health-related quality of life effects of once-daily cetirizine HCl in patients with seasonal allergic rhinitis: a randomized double-blind, placebo-controlled trial. Clin Exp Allergy 2003; 33: 351–8

    PubMed  CAS  Article  Google Scholar 

  257. Gillman SA, Blatter M, Condemi JJ, et al. The health-related quality of life effects of once-daily cetirizine HCl syrup in children with seasonal allergic rhinitis. Clin Pediatr 2002; 41: 687–96

    Article  Google Scholar 

  258. Horak F, Stübner UP, Zieglmayer R, et al. Controlled comparison of the efficacy and safety of cetirizine 10mg od and fexofenadine 120mg od in reducing symptoms of seasonal allergic rhinitis. Int Arch Allergy Immunol 2001; 125: 73–9

    PubMed  CAS  Article  Google Scholar 

  259. Howarth PH, Stern MA, Roi L, et al. Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180mg once daily) and cetirizine in seasonal allergic rhinitis. J Allergy Clin Immunol 1999; 104: 927–33

    PubMed  CAS  Article  Google Scholar 

  260. Hampel F, Ratner P, Mansfield L, et al. Fexofenadine hydrochloride, 180 mg, exhibits equivalent efficacy to cetirizine, 10 mg, with less drowsiness in patients with moderate-to-severe seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2003; 91: 354–61

    PubMed  CAS  Article  Google Scholar 

  261. Day JH, Briscoe MP, Clark RH, et al. Onset of action and efficacy of terfenadine, astemizole, cetirizine, and loratadine for the relief of symptoms of allergic rhinitis. Ann Asthma Allergy Immunol 1997; 79: 163–72

    CAS  Article  Google Scholar 

  262. Day JH, Briscoe M, Widlitz MD. Cetirizine, loratadine, or placebo in subjects with seasonal allergic rhinitis: effects after controlled ragweed pollen challenge in an environmental exposure unit. J Allergy Clin Immunol 1998; 101: 638–45

    PubMed  CAS  Article  Google Scholar 

  263. Nayak AS, Schenkel E. Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis. Allergy 2001; 56: 1077–80

    PubMed  CAS  Article  Google Scholar 

  264. Salmun LM, Lorber R, Danzig M, et al. Efficacy and safety of desloratadine in seasonal allergic rhinitis [abstract no. 1123]. J Allergy Clin Immunol 2000; 104 Suppl. 1: 384–5

    Article  Google Scholar 

  265. Heithoff K, Meltzer EO, Mellars L, et al. Desloratadine improves quality of life in patients with seasonal allergic rhinitis [abstract no. 1121]. J Allergy Clin Immunol 2000; 104 Suppl. 1: 383–4

    Article  Google Scholar 

  266. Meltzer EO, Prenner BM, Nayak A. Efficacy and tolerability of once-daily 5mg desloratadine, an H1-receptor antagonist, in patients with seasonal allergic rhinitis: assessment during the spring and fall allergy seasons. Clin Drug Invest 2001; 21: 25–32

    CAS  Article  Google Scholar 

  267. Berger WE, Schenkel EJ, Mansfield LE, et al. Safety and efficacy of desloratadine 5mg in asthma patients with seasonal allergic rhinitis and nasal congestion. Ann Allergy Asthma Immunol 2002; 89: 485–91

    PubMed  CAS  Article  Google Scholar 

  268. Salmun LM, Lorber R. 24-hour efficacy of once-daily desloratadine therapy in patients with seasonal allergic rhinitis. BMC Fam Pract 2002; 3: 14–20

    PubMed  Article  Google Scholar 

  269. Wilson AM, Haggart K, Sims EJ, et al. Effects of fexofenadine and desloratadine on subjective and objective measures of nasal congestion in seasonal allergic rhinitis. Clin Exp Allergy 2002; 32: 1504–9

    PubMed  CAS  Article  Google Scholar 

  270. Day JH, Briscoe MP, Welsh A, et al. Onset of action, efficacy, and safety of a single dose of fexofenadine hydrochloride for ragweed allergy using an environmental exposure unit. Ann Allergy Asthma Immunol 1997; 79: 533–40

    PubMed  CAS  Article  Google Scholar 

  271. Wahn U, Meltzer EO, Finn AF, et al. Fexofenadine is efficacious and safe in children (aged 6–11 years) with seasonal allergic rhinitis. J Allergy Clin Immunol 2003; 111: 763–9

    PubMed  CAS  Article  Google Scholar 

  272. Sussman GL, Mason J, Compton D, et al. The efficacy and safety of fexofenadine HCl and pseudoephedrine, alone and in combination, in seasonal allergic rhinitis. J Allergy Clin Immunol 1999; 104: 100–6

    PubMed  CAS  Article  Google Scholar 

  273. Casale TB, Andrade C, Qu R. Safety and efficacy of once-daily fexofenadine HCl in the treatment of autumn seasonal allergy rhinitis. Allergy Asthma Proc 1999; 20: 193–8

    PubMed  CAS  Article  Google Scholar 

  274. Bronsky EA, Falliers CJ, Kaiser HB, et al. Effectiveness and safety of fexofenadine, a new nonsedating H1-receptor antagonist, in the treatment of fall allergies. Allergy Asthma Proc 1998; 19: 135–41

    PubMed  CAS  Article  Google Scholar 

  275. Meltzer EO, Casale TB, Nathan RA, et al. Once-daily fexofenadine HCl improves quality of life and reduces work and activity impairment in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1999; 83: 311–7

    PubMed  CAS  Article  Google Scholar 

  276. Bernstein DI, Schoenwetter WF, Nathan RA, et al. Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1997; 79: 443–8

    PubMed  CAS  Article  Google Scholar 

  277. van Cauwenberge P, Juniper EF, Meltzer EO, et al. Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120mg, loratadine 10mg and placebo administered once daily for the treatment of seasonal allergic rhinitis. Clin Exp Allergy 2000; 30: 891–9

    PubMed  Article  Google Scholar 

  278. Mösges R, van Cauwenberg P, Purello-D’Ambrosio F, et al. Fexofenadine and loratadine exhibit rapid relief, but only fexofenadine maintains efficacy over a 2-week period [abstract no. 1005]. Allergy 2000; 55 Suppl. 63: 281

    Google Scholar 

  279. Ricard N, Kind P, Christian S, et al. Link between preferences and treatment outcomes in seasonal allergic rhinitis: an empiric investigation. Clin Ther 1999; 20: 268–77

    Article  Google Scholar 

  280. Serra HA, Alves O, Rizzo LFL, et al. Loratadine-pseudoephedrine in children with allergic rhinitis, a controlled double-blind trial. Br J Clin Pharmacol 1998; 45: 147–50

    PubMed  CAS  Article  Google Scholar 

  281. Druce HM, Thoden WR, Mure P, et al. Brompheniramine, loratadine, and placebo in allergic rhinitis: a placebo-controlled comparative trial. J Clin Pharmacol 1998; 38: 382–9

    PubMed  CAS  Google Scholar 

  282. Harvey RP, Comer C, Sanders B, et al. Model for outcomes assessment of antihistamine use for seasonal allergic rhinitis. J Allergy Clin Immunol 1996; 97: 1233–41

    PubMed  CAS  Article  Google Scholar 

  283. Grant JA, Nicodemus CF, Findlay SR, et al. Cetirizine in patients with seasonal rhinitis and concomitant asthma: prospective, randomized, placebo-controlled trial. J Allergy Clin Immunol 1995; 95: 923–35

    PubMed  CAS  Article  Google Scholar 

  284. Baena-Cagnani CE. Desloratadine activity in concurrent seasonal allergic rhinitis and asthma. Allergy 2001; 56 Suppl. 65: 21–7

    PubMed  Google Scholar 

  285. Corren J. Desloratadine reduces the use of inhaled beta2-agonists and improves asthma symptoms in patients with seasonal allergic rhinitis and asthma [abstract no. 535]. J Allergy Clin Immunol 2001; 107 Suppl. 1: 163

    Google Scholar 

  286. Ratner PH. Long-term benefit of desloratadine against seasonal allergic rhinitis symptoms in patients with asthma [abstract no. 531]. J Allergy Clin Immunol 2001; 107 Suppl. 1: 161

    Google Scholar 

  287. Corren J, Harris AG, Aaronson D, et al. Efficacy and safety of loratadine plus pseudoephedrine in patients with seasonal allergic rhinitis and mild asthma. J Allergy Clin Immunol 1997; 100: 781–8

    PubMed  CAS  Article  Google Scholar 

  288. Aubier M, Neukirch C, Peiffer C, et al. Effect of cetirizine on bronchial hyperresponsiveness in patients with seasonal allergic rhinitis and asthma. Allergy 2001; 56: 35–42

    PubMed  CAS  Article  Google Scholar 

  289. Grant JA. The clinical efficacy of antihistamines in the upper and lower airway. Clin Exp Allergy 1997; 27 Suppl. 2: 38–46

    PubMed  CAS  Article  Google Scholar 

  290. Larsen JS. Do antihistamines have a role in asthma therapy? Pharmacotherapy 2001; 21 (3 Suppl.): 28–33

    Article  Google Scholar 

  291. Malick A, Grant JA. Antihistamines in the treatment of asthma. Allergy 1997; 52 Suppl. 34: 55–66

    PubMed  CAS  Article  Google Scholar 

  292. Meltzer EO. The use of anti-H1 drugs in mild asthma. Allergy 1995; 50: 41–7

    PubMed  CAS  Article  Google Scholar 

  293. Nelson HS. Prospects for antihistamines in the treatment of asthma. J Allergy Clin Immunol 2003; 112 (4 Suppl.): 96–100

    Article  Google Scholar 

  294. Simons FER. Is antihistamine (H1-receptor antagonist) therapy useful in clinical asthma? Clin Exp Allergy 1999; 29 Suppl. 3: 98–104

    PubMed  CAS  Article  Google Scholar 

  295. Adams RJ, Fuhlbrigge AL, Finkelstein JA, et al. Intranasal steroids and the risk of emergency department visits for asthma. J Allergy Clin Immunol 2002; 109: 636–42

    PubMed  CAS  Article  Google Scholar 

  296. Crystal-Peters J, Neslusan C, Crown WH, et al. Treating allergic rhinitis in patients with comorbid asthma: the risk of asthma-related hospitalizations and emergency department visits. J Allergy Clin Immunol 2002; 109: 57–62

    PubMed  Article  Google Scholar 

  297. Prenner BM, Capano D, Harris AG. Efficacy and tolerability of loratadine versus fexofenadine in the treatment of seasonal allergic rhinitis: a double-blind comparison with crossover treatment of nonresponders. Clin Ther 2000; 22: 760–9

    PubMed  CAS  Article  Google Scholar 

  298. Glass DJ, Harper AS. Assessing satisfaction with desloratadine and fexofenadine in allergy patients who report dissatisfaction with loratadine. BMC Fam Pract 2003; 4: 10–28

    PubMed  Article  Google Scholar 

  299. Ciprandi G, Tosca M, Passalacqua G, et al. Long-term cetirizine treatment reduces allergic symptoms and drug prescriptions in children with mite allergy. Ann Allergy Asthma Immunol 2001; 87: 223–6

    Article  Google Scholar 

  300. Aaronson DW. Evaluation of cetirizine in patients with allergic rhinitis and perennial asthma. Ann Allergy Asthma Immunol 1996; 76: 440–6

    PubMed  CAS  Article  Google Scholar 

  301. Mansmann Jr HC, Altman RA, Berman B A, et al. Efficacy and safety of cetirizine therapy in perennial allergic rhinitis. Ann Allergy 1992; 68: 348–53

    PubMed  Google Scholar 

  302. Jobst S, van den Wijngaart W, Schubert A, et al. Assessment of the efficacy and safety of three dose levels of cetirizine given once daily in children with perennial allergic rhinitis. Allergy 1994; 49: 598–604

    PubMed  CAS  Article  Google Scholar 

  303. Lai D-S, Lue K-H, Hsieh J-C, et al. The comparison of the efficacy and safety of cetirizine, oxatomide, ketotifen, and a placebo for the treatment of childhood perennial allergic rhinitis. Ann Allergy Asthma Immunol 2002; 89: 589–98

    PubMed  CAS  Article  Google Scholar 

  304. Horak F, Toth J, Marks B, et al. Efficacy and safety relative to placebo of an oral formulation of cetirizine and sustained-release pseudoephedrine in the management of nasal congestion. Allergy 1998; 53: 849–56

    PubMed  CAS  Article  Google Scholar 

  305. Bousquet J, Duchateau J, Pignat JC, et al. Improvement of quality of life by treatment with cetirizine in patients with perennial allergic rhinitis as determined by a French version of the SF-36 questionnaire. J Allergy Clin Immunol 1996; 98: 309–16

    PubMed  CAS  Article  Google Scholar 

  306. Rinne J, Simola M, Malmberg H, et al. Early treatment of perennial rhinitis with budesonide or cetirizine and its effect on long-term outcome. J Allergy Clin Immunol 2002; 109: 426–32

    PubMed  CAS  Article  Google Scholar 

  307. Sienra-Monge JJ, Gazca-Aguilar A, Rio-Navarro B. Double-blind comparison of cetirizine and loratadine in children ages 2 to 6 years with perennial allergic rhinitis. Am J Ther 1999; 6: 149–55

    PubMed  CAS  Article  Google Scholar 

  308. Simons FER, Prenner BM, Finn Jr A, et al. Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis. J Allergy Clin Immunol 2003; 111: 617–22

    PubMed  CAS  Article  Google Scholar 

  309. Ciprandi G, Cosentino C, Milanese M, et al. Fexofenadine reduces nasal congestion in perennial allergic rhinitis. Allergy 2001; 56: 1068–70

    PubMed  CAS  Article  Google Scholar 

  310. Crawford WW, Klaustermeyer WB, Lee PH, et al. Comparative efficacy of terfenadine, loratadine, and astemizole in perennial allergic rhinitis. Otolaryngol Head Neck Surg 1998; 118: 668–73

    PubMed  CAS  Google Scholar 

  311. Canonica GW, Ciprandi G. Fexofenadine treatment reduces nasal congestion in persistent allergic rhinitis [abstract no. 277]. J Allergy Clin Immunol 2002; 109 Suppl. 1: 102

    Article  Google Scholar 

  312. Bachert C. Decongestant efficacy of desloratadine in patients with seasonal allergic rhinitis. Allergy 2001; 56 Suppl. 65: 14–20

    PubMed  Article  Google Scholar 

  313. Nayak A, Lorber R, Salmun LM. Decongestant effects of desloratadine in patients with seasonal allergic rhinitis [abstract no. 1122]. J Allergy Clin Immunol 2000; 104 Suppl. 1: 384

    Article  Google Scholar 

  314. Shapiro G. Decongestant effects of desloratadine in patients with seasonal allergic rhinitis and asthma [abstract no. 531]. J Allergy Clin Immunol 2001; 107 Suppl. 1: 161

    Google Scholar 

  315. Burtin B, Duchateau J, Pignat JC, et al. Further improvement of quality of life by cetirizine in perennial allergic rhinitis as a function of treatment duration. Invest Allergol Clin Immunol 2000; 10: 66–70

    CAS  Google Scholar 

  316. Lee EE, Maibach HI. Treatment of urticaria: an evidence-based evaluation of antihistamines. Am J Clin Dermatol 2001; 2: 27–32

    PubMed  CAS  Article  Google Scholar 

  317. Prenner BM. The evolution of pharmacotherapy for rhinitis and urticaria. Allergy Asthma Proc 2001; 22: 277–80

    PubMed  CAS  Google Scholar 

  318. Tedeschi A, Airaghi L, Lorini M, et al. Chronic urticaria: a role for newer immunomodulatory drugs? Am J Clin Dermatol 2003; 4: 297–305

    PubMed  Article  Google Scholar 

  319. Tharp MD. Chronic urticaria: pathophysiology and treatment approaches. J Allergy Clin Immunol 1996; 98 (6 Pt 3): 325–30

    Article  Google Scholar 

  320. Kaplan AP. Chronic urticaria: pathogenesis and treatment. J Allergy Clin Immunol 2004; 114: 465–74

    PubMed  CAS  Article  Google Scholar 

  321. Wanderer AA, Bernstein IL, Goodman DL, et al. The diagnosis and management of urticaria: a practice parameter, part II: chronic urticaria/angioedema. Ann Allergy Asthma Immunol 2000; 85: 532–44

    Article  Google Scholar 

  322. Zuberbier T, Greaves MW, Juhlin L, et al. Management of urticaria: a consensus report. J Invest Dermatol 2001; 6: 128–31

    CAS  Article  Google Scholar 

  323. Grattan CEH, O’Donnell BF, Francis DM, et al. Randomized double-blind study of cyclosporin in chronic ‘idiopathic’ urticaria. Br J Dermatol 2000; 143: 365–72

    PubMed  CAS  Article  Google Scholar 

  324. Pacor ML, Di Lorenzo G, Corrocher R. Efficacy of leukotriene receptor antagonist in chronic urticaria: a double-blind, placebo-controlled comparison of treatment with montelukast and cetirizine in patients with chronic urticaria with intolerance to food additive and/or acetylsalicylic acid. Clin Exp Allergy 2001; 31: 1607–14

    PubMed  CAS  Article  Google Scholar 

  325. Breneman DL. Cetirizine versus hydroxyzine and placebo in chronic idiopathic urticaria. Ann Pharmacother 1996; 30: 1075–9

    PubMed  CAS  Google Scholar 

  326. La Rosa M, Leonardi S, Marchese G, et al. Double-blind multicenter study on the efficacy and tolerability of cetirizine compared with oxatomide in chronic idiopathic urticaria in preschool children. Ann Allergy Asthma Immunol 2001; 87: 48–53

    PubMed  Article  Google Scholar 

  327. Henz BM, Metzenauer P, O’Keefe E, et al. Differential effects of new-generation H1-receptor antagonists in pruritic dermatoses. Allergy 1998; 53: 180–3

    PubMed  CAS  Article  Google Scholar 

  328. Tharp MD. Cetirizine: a new therapeutic alternative for chronic urticaria. Cutis 1996; 58: 94–8

    PubMed  CAS  Google Scholar 

  329. Handa S, Dogra S, Kumar B. Comparative efficacy of cetirizine and fexofenadine in the treatment of chronic idiopathic urticaria. J Dermatolog Treat 2004; 15: 55–7

    PubMed  CAS  Article  Google Scholar 

  330. Ring J, Hein R, Gauger A. Desloratadine in the treatment of chronic idiopathic urticaria. Allergy 2001; 56 Suppl. 65: 28–32

    PubMed  Article  Google Scholar 

  331. Ring J, Hein R, Gauger A, et al. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Int J Dermatol 2001; 40: 72–6

    PubMed  CAS  Article  Google Scholar 

  332. Monroe E, Finn A, Patel P, et al. Efficacy and safety of desloratadine 5mg once daily in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. J Am Acad Dermatol 2003; 48: 535–41

    PubMed  Article  Google Scholar 

  333. Nettis E, Dambra P, D’Oronzio L, et al. Comparison of montelukast and fexofenadine for chronic idiopathic urticaria. Arch Dermatol 2001; 137: 99–100

    PubMed  CAS  Google Scholar 

  334. Finn AF, Kaplan AP, Fretwell R, et al. A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria. J Allergy Clin Immunol 1999; 103: 1071–8

    Article  Google Scholar 

  335. Nelson HS, Reynolds R, Mason J. Fexofenadine HCl is safe and effective for treatment of chronic idiopathic urticaria. Ann Allergy Asthma Immunol 2000; 84: 517–22

    PubMed  CAS  Article  Google Scholar 

  336. Monroe EW. Safety and efficacy of loratadine in urticaria. Int J Dermatol 1996; 35: 837–41

    PubMed  CAS  Article  Google Scholar 

  337. Monroe EW. Loratadine in the treatment of urticaria. Clin Ther 1997; 19: 232–42

    PubMed  CAS  Article  Google Scholar 

  338. Thompson AK, Finn AF, Schoenwetter WF. Effect of 60mg twice-daily fexofenadine HCl on quality of life, work and classroom productivity, and regular activity in patients with chronic idiopathic urticaria. J Am Acad Dermatol 2000; 43: 24–30

    PubMed  CAS  Article  Google Scholar 

  339. Purello-D’Ambrosio F, Isola S, Ricciardi L, et al. A controlled study on the effectiveness of loratadine in combination with flunisolide in the treatment of nonallergic rhinitis with eosinophilia (NARES). Clin Exp Allergy 1999; 29: 1143–7

    PubMed  Article  Google Scholar 

  340. Haye R, Aanesen JP, Burtin B, et al. The effect of cetirizine on symptoms and signs of nasal polyposis. J Laryngol Otol 1998; 112: 1042–6

    PubMed  CAS  Article  Google Scholar 

  341. Ciprandi G, Tosca M, Ricca V, et al. Cetirizine treatment of allergic cough in children with pollen allergy. Allergy 1997; 52: 752–4

    PubMed  CAS  Article  Google Scholar 

  342. Diepgen TL, Warner JO, Businco L, et al. Long-term treatment with cetirizine of infants with atopic dermatitis: a multi-country, double-blind, randomized, placebo-controlled trial (the ETAC™ trial) over 19 months. Pediatr Allergy Immunol 2002; 13: 278–86

    PubMed  Article  Google Scholar 

  343. Juhlin L. Nonclassical clinical indications for H1-receptor antagonists in dermatology. Allergy 1995; 50: 36–40

    PubMed  CAS  Article  Google Scholar 

  344. La Rosa M, Ranno C, Musarra I, et al. Double-blind study of cetirizine in atopic eczema in children. Ann Allergy Asthma Immunol 1994; 73: 117–22

    Google Scholar 

  345. Simons FER. Prospective, long-term safety evaluation of the H1-receptor antagonist cetirizine in very young children with atopic dermatitis. J Allergy Clin Immunol 1999; 104: 433–40

    PubMed  CAS  Article  Google Scholar 

  346. Simons FER. Prevention of acute urticaria in young children with atopic dermatitis. J Allergy Clin Immunol 2001; 107: 703–6

    PubMed  CAS  Article  Google Scholar 

  347. Warner JO. A double-blinded, randomized, placebo-controlled trial of cetirizine in preventing the onset of asthma in children with atopic dermatitis: 18 months’ treatment and 18 months’ posttreatment follow-up. J Allergy Clin Immunol 2001; 108: 929–37

    PubMed  CAS  Article  Google Scholar 

  348. Canonica GW, Ciprandi G. Minimal persistent inflammation may be controlled by cetirizine. Ann Allergy Asthma Immunol 1999; 83: 445–8

    PubMed  CAS  Article  Google Scholar 

  349. Wanderer AA, Bernstein IL, Goodman DL, et al. The diagnosis and management of urticaria: a practice parameter, part I: acute urticaria/angioedema. Ann Allergy Asthma Immunol 2000; 85: 525–31

    Article  Google Scholar 

  350. Zuberbier T, Aberer W, Burtin B, et al. Efficacy of cetirizine in cholinergic urticaria. Acta Derm Venereol 1995; 75: 147–9

    PubMed  CAS  Google Scholar 

  351. Zuberbier T, Münzberger C, Haustein U, et al. Double-blind crossover study of high-dose cetirizine in cholinergic urticaria. Dermatology 1996; 193: 324–7

    PubMed  CAS  Article  Google Scholar 

  352. Monfrecola G, Masturzo E, Riccardo AM, et al. Cetirizine for solar urticaria in the visible spectrum. Dermatology 2000; 200: 334–5

    PubMed  CAS  Article  Google Scholar 

  353. Aroni K, Vivaliotis M, Liossi A, et al. Eosinophilic cellulitis in a child successfully treated with cetirizine [letter]. Acta Derm Venereol 1999; 79: 332

    PubMed  CAS  Article  Google Scholar 

  354. Baker RAU, Zeller RA, Klein RL, et al. Burn wound itch control using H1 and H2 antagonists. J Burn Care Rehabil 2001; 22: 263–8

    PubMed  CAS  Article  Google Scholar 

  355. Juhlin L. Inhibition of cold urticaria by desloratadine. J Dermatolog Treat 2004; 15: 51–4

    PubMed  CAS  Article  Google Scholar 

  356. Kawashima M, Tango T, Noguchi T, et al. Addition of fexofenadine to a topical corticosteroid reduces the pruritus associated with atopic dermatitis in a 1-week randomized, multicentre, double-blind, placebo-controlled parallel-group study. Br J Dermatol 2003; 148: 1212–21

    PubMed  CAS  Article  Google Scholar 

  357. Çayan S, Apa DD, Akbay E. Effect of fexofenadine, a mast cell blocker, in infertile men with significantly increased testicular mast cells. Asian J Androl 2002; 4: 291–4

    PubMed  Google Scholar 

  358. Allegra® (fexofenadine hydrochloride) capsules and tablets: package insert. Kansas City (MO): Aventis Pharmaceuticals Inc., 2003

  359. Claritin® (loratadine) tablets, syrup, and rapidly-disintegrating tablets: package insert. Kenilworth (NJ): Schering Corporation, 2000

  360. Zyrtec® (cetirizine hydrochloride) tablets and syrup: package insert. New York: Pfizer Inc., 2002

  361. Simons FER. Non-cardiac adverse effects of antihistamines (H1-receptor antagonists). Clin Exp Allergy 1999; 29 Suppl. 3: 125–32

    PubMed  CAS  Article  Google Scholar 

  362. Timmerman H. Factors involved in the absence of sedative effects by second-generation antihistamines. Allergy 2000; 55 Suppl. 60: 5–10

    PubMed  Article  Google Scholar 

  363. Adelsberg BR. Sedation and performance issues in the treatment of allergic conditions. Arch Intern Med 1997; 157: 494–500

    PubMed  CAS  Article  Google Scholar 

  364. Horak F, Stübner UP. Comparative tolerability of second generation antihistamines. Drug Saf 1999; 20: 385–401

    PubMed  CAS  Article  Google Scholar 

  365. Mattila MJ, Paakkari I. Variations among non-sedating antihistamines: are there real differences? Eur J Clin Pharmacol 1999; 55: 85–93

    PubMed  CAS  Article  Google Scholar 

  366. Philpott EE. Safety of second generation antihistamines. Allergy Asthma Proc 2000; 21: 15–20

    Article  Google Scholar 

  367. Simons FER. H1-receptor antagonists: comparative tolerability and safety. Drug Saf 1994; 10: 350–80

    PubMed  CAS  Article  Google Scholar 

  368. Craig-McFeely PM, Acharya NV, Shakir SAW. Evaluation of the safety of fexofenadine from experience gained in general practice in England in 1997. Eur J Clin Pharmacol 2001; 57: 313–20

    PubMed  CAS  Article  Google Scholar 

  369. Mason J, Reynolds R, Rao N. The systemic safety of fexofenadine HCl. Clin Exp Allergy 1999; 29 Suppl. 3: 163–70

    PubMed  CAS  Article  Google Scholar 

  370. Mann RD, Pearce GL, Dunn N, et al. Sedation with ‘non-sedating’ antihistamines: four prescription-event monitoring studies in general practice. BMJ 2000; 320: 1184–7

    PubMed  CAS  Article  Google Scholar 

  371. Levander S. CNS effects in the correct perspective. Allergy 2000; 55 Suppl. 55: 35–9

    PubMed  Article  Google Scholar 

  372. Marshall PS, O’Hara C, Steinberg P. Effects of seasonal allergic rhinitis on selected cognitive abilities. Ann Allergy Asthma Immunol 2000; 84: 403–10

    PubMed  CAS  Article  Google Scholar 

  373. Spaeth J, Klimek SJ, Mösages R. Sedation in allergic rhinitis is caused by the condition and not by antihistamine treatment. Allergy 1996; 51: 893–906

    PubMed  CAS  Google Scholar 

  374. Hindmarch I. Psychometric aspects of antihistamines. Allergy 1995; 50: 48–54

    PubMed  CAS  Article  Google Scholar 

  375. Sannita WG, Crimi E, Riela S, et al. Cutaneous antihistaminic action of cetirizine and dose-related EEG concomitants of sedation in man. Eur J Pharmacol 1996; 300: 33–41

    PubMed  CAS  Article  Google Scholar 

  376. Simons FER, Fraser TG, Maher J, et al. Central nervous system effects of H1-receptor antagonists in the elderly. Ann Allergy Asthma Immunol 1999; 82: 157–60

    PubMed  CAS  Article  Google Scholar 

  377. Simons FER, Fraser TG, Reggin JD, et al. Comparison of the central nervous system effects produced by six H1-receptor antagonists. Clin Exp Allergy 1996; 26: 1092–7

    PubMed  CAS  Article  Google Scholar 

  378. Simons FER, Fraser TG, Reggin JD, et al. Individual differences in central nervous system response to antihistamines (H1-receptor antagonists). Ann Allergy Asthma Immunol 1995; 75: 507–14

    PubMed  CAS  Google Scholar 

  379. Ng KH, Chong D, Wong CK, et al. Central nervous system side effects of first- and second-generation antihistamines in school children with perennial allergic rhinitis: a randomized, double-blind, placebo-controlled comparative study. Pediatrics 2004; 113: 116–21

    Article  Google Scholar 

  380. Salmun LM, Gates D, Scharf M, et al. Loratadine versus cetirizine: assessment of somnolence and motivation during the workday. Clin Ther 2000; 22: 573–82

    PubMed  CAS  Article  Google Scholar 

  381. Scharf MB, Kay G, Rikken G, et al. Desloratadine has no effect on wakefulness or psychomotor performance [abstract no. 1001]. Allergy 2000; 55 Suppl. 63: 280

    Google Scholar 

  382. Tashiro M, Sakurada Y, Iwabuchi K, et al. Central effects of fexofenadine and cetirizine: measurement of psychomotor performance, subjective sleepiness, and brain histamine H1-receptor occupancy using 11C-doxepin positron emission tomography. J Clin Pharmacol 2004; 44: 890–900

    PubMed  CAS  Article  Google Scholar 

  383. Ramaekers JG, Uiterwijk MMC, O’Hanlon JF. Effects of loratadine and cetirizine on actual driving and psychometric test performance, and EEG during driving. Eur J Clin Pharmacol 1992; 42: 363–9

    PubMed  CAS  Google Scholar 

  384. Vermeeren A, Ramaekers JG, O’Hanlon JF. Effects of emedastine and cetirizine, alone and with alcohol, on actual driving of males and females. J Psychopharmacol 2002; 16: 57–64

    PubMed  CAS  Article  Google Scholar 

  385. Gengo FM, Gabos C, Mechtler L. Quantitative effects of cetirizine and diphenhydramine on mental performance measured using an automobile driving simulator. Ann Allergy 1990; 64: 520–6

    PubMed  CAS  Google Scholar 

  386. Gengo FM, Gabos C. Antihistamines, drowsiness, and psychomotor impairment: central nervous system effect of cetirizine. Ann Allergy 1987; 59 (6 pt 2): 53–7

    PubMed  CAS  Google Scholar 

  387. Nicholson AN, Turner C. Central effects of the H1-antihistamine, cetirizine. Aviat Space Environ Med 1998; 69: 166–71

    PubMed  CAS  Google Scholar 

  388. Walsh JK, Muehlbach MJ, Schweitzer PK. Simulated assembly line performance following ingestion of cetirizine or hydrox-yzine. Ann Allergy 1992; 69: 195–200

    PubMed  CAS  Google Scholar 

  389. Hindmarch I, Johnson S, Meadows R, et al. The acute and sub-chronic effects of levocetirizine, cetirizine, loratadine, promethazine and placebo on cognitive function, psychomotor function, psychomotor performance, and weal and flare. Curr Med Res Opin 2001; 17: 241–55

    PubMed  CAS  Google Scholar 

  390. Nicholson AN, Handford ADF, Turner C, et al. Studies on performance and sleepiness with the H1-antihistamine, desloratadine. Aviat Space Environ Med 2003; 74: 809–15

    PubMed  CAS  Google Scholar 

  391. Satish U, Streufert S, Dewan M, et al. Improvements in simulated real-world relevant performance for patients with seasonal allergic rhinitis: impact of desloratadine. Allergy 2004; 59: 415–20

    PubMed  CAS  Article  Google Scholar 

  392. Vuurman EFPM, Rikken GH, Muntjewerff ND, et al. Effects of desloratadine, diphenhydramine, and placebo on driving performance and psychomotor performance measurements. Eur J Clin Pharmacol 2004; 60: 307–13

    PubMed  CAS  Article  Google Scholar 

  393. Valk PJL, Van Roon DB, Simons RM, et al. Desloratadine shows no effect on performance during 6 h at 8,000 ft simulated cabin altitude. Aviat Space Environ Med 2004; 75: 433–8

    PubMed  Google Scholar 

  394. Hindmarch I, Shamsi Z, Kimber S. An evaluation of the effects of high-dose fexofenadine on the central nervous system: a double-blind, placebo-controlled study in healthy volunteers. Clin Exp Allergy 2002; 32: 133–9

    PubMed  CAS  Article  Google Scholar 

  395. Potter PC, Schepers JM, Van Niekerk CH. The effects of fexofenadine on reaction time, decision-making, and driver behavior. Ann Allergy Asthma Immunol 2003; 91: 177–81

    PubMed  CAS  Article  Google Scholar 

  396. Bower EA, Moore JL, Moss M, et al. The effects of single-dose fexofenadine, diphenhydramine, and placebo on cognitive performance in flight personnel. Aviat Space Environ Med 2003; 74: 145–52

    PubMed  CAS  Google Scholar 

  397. Vermeeren A, O’Hanlon JF. Fexofenadine’s effects, alone and with alcohol, on actual driving and psychomotor performance. J Allergy Clin Immunol 1998; 101: 306–11

    PubMed  CAS  Article  Google Scholar 

  398. Nicholson AN, Stone BM, Turner C, et al. Antihistamines and aircrew: usefulness of fexofenadine. Aviat Space Environ Med 2000; 71: 2–6

    PubMed  CAS  Google Scholar 

  399. Kamei H, Noda Y, Ishikawa K, et al. Comparative study of acute effects of single doses of fexofenadine, olopatadine, d-chlorpheniramine and placebo on psychomotor function in healthy volunteers. Hum Psychopharmacol Clin Exp 2003; 18: 611–8

    CAS  Article  Google Scholar 

  400. Weiler JM, Bloomfield JR, Woodworth GG, et al. Effects of fexofenadine, diphenhydramine, and alcohol on driving performance: a randomized, placebo-controlled trial in the Iowa Driving Simulator. Ann Intern Med 2000; 132: 354–63

    PubMed  CAS  Google Scholar 

  401. Ridout F, Shamsi Z, Meadows R, et al. A single-center, randomized, double-blind, placebo-controlled, crossover investigation of the effects of fexofenadine hydrochloride 180mg alone and with alcohol, with hydroxyzine hydrochloride 50mg as a positive internal control, on aspects of cognitive and psychomotor function related to driving a car. Clin Ther 2003; 25: 1518–38

    PubMed  CAS  Article  Google Scholar 

  402. Valk PJ, Simons RM, Struyvenberg PA, et al. Effects of a single dose of loratadine on flying ability under conditions of simulated cabin pressure. Am J Rhinol 1997; 11: 27–33

    PubMed  CAS  Article  Google Scholar 

  403. Volkerts ER, Van Laar M. Specific review of the psychometric effects of cetirizine. Allergy 1995; 50: 55–60

    PubMed  CAS  Article  Google Scholar 

  404. Shamsi Z, Kimber S, Hindmarch I. An investigation into the effects of cetirizine on cognitive function and psychomotor performance in healthy volunteers. Eur J Clin Pharmacol 2001; 56: 865–71

    PubMed  CAS  Article  Google Scholar 

  405. Stevenson J, Cronah D, Evrard P, et al. Long-term evaluation of the impact of the H1-receptor antagonist cetirizine on the behavioral, cognitive, and psychomotor development of very young children with atopic dermatitis. Pediatr Res 2002; 52: 251–7

    PubMed  CAS  Article  Google Scholar 

  406. Wilken JA, Kane RL, Ellis AK, et al. A comparison of the effect of diphenhydramine and desloratadine on vigilance and cognitive function during treatment of ragweed-induced allergic rhinitis. Ann Allergy Asthma Immunol 2003; 91: 375–85

    PubMed  CAS  Article  Google Scholar 

  407. Stone BM, Turner C, Mills SL, et al. Studies into the possible central effects of the H-1 receptor antagonist fexofenadine. Int Arch Allergy Immunol 1999; 118: 338

    PubMed  CAS  Article  Google Scholar 

  408. Hindmarch I, Shamsi Z, Stanley N, et al. A double-blind, placebo-controlled investigation of the effects of fexofenadine, loratadine and promethazine on cognitive and psychomotor function. Br J Clin Pharmacol 1999; 48: 200–6

    PubMed  CAS  Article  Google Scholar 

  409. Mansfield L, Mendoza C, Flores J, et al. Effects of fexofenadine, diphenhydramine, and placebo on performance of the Test of Variables of Attention (TOVA). Ann Allergy Asthma Immunol 2003; 90: 555–8

    Article  Google Scholar 

  410. Ridout F, Hindmarch I. The effects of acute doses of fexofenadine, promethazine, and placebo on cognitive and psychomotor function in healthy Japanese volunteers. Ann Allergy Asthma Immunol 2003; 90: 404–10

    PubMed  CAS  Article  Google Scholar 

  411. Bender BG, McCormick DR, Milgrom H. Children’s school performance is not impaired by short-term administration of diphenhydramine or loratadine. J Pediatr 2001; 138: 656–60

    PubMed  CAS  Article  Google Scholar 

  412. Gaillard AWK, Gruisen A, de Jong R. The influence of antihistamines on human performance. Eur J Clin Pharmacol 1988; 35: 249–53

    PubMed  CAS  Article  Google Scholar 

  413. Kay GG, Berman B, Mockoviak SH, et al. Initial and steady-state effects of diphenhydramine and loratadine or sedation, cognition, mood, and psychomotor. Arch Intern Med 1997; 157: 2350–6

    PubMed  CAS  Article  Google Scholar 

  414. Bradley CM, Nicholson AN. Studies on the central effects of the H1-antagonist, loratadine. Eur J Clin Pharmacol 1987; 32: 419–21

    PubMed  CAS  Article  Google Scholar 

  415. Bender BG, Berning S, Dudden R, et al. Sedation and performance impairment of diphenhydramine and second-generation antihistamines: a meta-analysis. J Allergy Clin Immunol 2003; 111: 770–6

    PubMed  CAS  Article  Google Scholar 

  416. Finkle WD, Adams JL, Greenland S, et al. Increased risk of serious injury following an initial prescription for diphenhydramine. Ann Allergy Asthma Immunol 2002; 89: 244–50

    PubMed  CAS  Article  Google Scholar 

  417. Hennessy S, Strom BL. Nonsedating antihistamines should be preferred over sedating antihistamines in patients who drive. Ann Intern Med 2000; 132: 405–6

    PubMed  CAS  Google Scholar 

  418. Mohler SR, Nicholson A, Harvey RP, et al. The use of antihistamines in safety-critical jobs: a meeting report. Curr Med Res Opin 2002; 18: 332–7

    PubMed  CAS  Article  Google Scholar 

  419. Casale TB, Blaiss MS, Gelfand E, et al. First do no harm: managing antihistamine impairment in patient with allergic rhinitis. J Allergy Clin Immunol 2003; 111 (5 Suppl.): 835–42

    Article  Google Scholar 

  420. O’Hanlon JF, Ramaekers JG. Antihistamine effects on actual driving performance in a standard test: a summary of Dutch experience, 1989–94. Allergy 1995; 50: 234–42

    PubMed  Article  Google Scholar 

  421. Woosley RL. Cardiac actions of antihistamines. Annu Rev Pharmacol Toxicol 1996; 36: 233–52

    PubMed  CAS  Article  Google Scholar 

  422. Woosley RL, Chen Y, Freiman JP, et al. Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993; 269: 1532–6

    PubMed  CAS  Article  Google Scholar 

  423. Colatsky TJ, Follmer CH, Starmer CF. Channel specificity in antiarrhythmic drug action: mechanism of potassium channel block and its role in suppressing and aggravating cardiac arrhythmias. Circulation 1990; 82: 2235–42

    PubMed  CAS  Article  Google Scholar 

  424. Sanguinetti MC. Modulation of potassium channels by antiarrhythmic and antihypertensive drugs. Hypertension 1992; 19: 228–36

    PubMed  CAS  Article  Google Scholar 

  425. Honig PK, Wortham DC, Zamani K, et al. Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences. JAMA 1993; 269: 1513–8

    PubMed  CAS  Article  Google Scholar 

  426. Gras J, Llenas J, Palacios JM, et al. The role of ketoconazole in the QTc interval prolonging effects of H1-antihistamines in a guinea-pig model of arrhythmogenicity. Br J Pharmacol 1996; 119: 187–8

    PubMed  CAS  Article  Google Scholar 

  427. Priori SG, Napolitano C, Paganini V, et al. Molecular biology of the long QT syndrome: impact on management. Pacing Clin Electrophysiol 1997; 20: 2052–7

    PubMed  CAS  Article  Google Scholar 

  428. Taglialatela M, Annunziato L. Evaluation of the cardiac safety of second-generation antihistamines. Allergy 2000; 55 Suppl. 60: 22–30

    PubMed  Article  Google Scholar 

  429. Taglialatela M, Castaldo P, Pannaccione A, et al. Cardiac ion channels and antihistamines: possible mechanisms of cardiotoxicity. Clin Exp Allergy 1999; 29 Suppl. 3: 182–9

    PubMed  CAS  Article  Google Scholar 

  430. De Ponti F, Poluzzi E, Montanaro N. QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience. Eur J Clin Pharmacol 2002; 56: 1–18

    Article  Google Scholar 

  431. Napolitano C, Priori SG, Schwartz PJ. Torsade de pointes: mechanisms and management. Drugs 1994; 47: 51–65

    PubMed  CAS  Article  Google Scholar 

  432. Viskin S. Long QT syndromes and torsade de pointes. Lancet 1999; 354: 1625–33

    PubMed  CAS  Article  Google Scholar 

  433. Llenas J, Cardelús I, Heredia A, et al. Cardiotoxicity of histamine and the possible role of histamine in the arrhythmogenesis produced by certain antihistamines. Drug Saf 1999; 21 Suppl. 1: 33–8

    PubMed  CAS  Article  Google Scholar 

  434. Cavero I, Mestre M, Guillon J-M, et al. Preclinical in vitro cardiac electrophysiology: a method of predicting arrhythmogenic potential of antihistamines in humans? Drug Saf 1999; 21 Suppl. 1: 19–31

    PubMed  CAS  Article  Google Scholar 

  435. Yap YG, Camm AJ. Arrhythmogenic mechanisms of non-sedating antihistamines. Clin Exp Allergy 1999; 29 Suppl. 3: 174–81

    PubMed  CAS  Article  Google Scholar 

  436. Yap YG, Camm AJ. Potential cardiac toxicity of H1-antihistamines. Clin Allergy Immunol 2002; 17: 389–419

    PubMed  CAS  Google Scholar 

  437. Belardinelli L, Antzelevitch C, Vos MA. Assessing predictors of drug-induced torsade de pointes. Trends Pharmacol Sci 2003; 24: 619–25

    PubMed  CAS  Article  Google Scholar 

  438. Carmeliet E. Effects of cetirizine on the delayed K+ currents in cardiac cells: comparison with terfenadine. Br J Pharmacol 1998; 124: 663–8

    PubMed  CAS  Article  Google Scholar 

  439. Hey JA, del Prado M, Sherwood J, et al. Comparative analysis of the cardiotoxicity proclivities of second generation antihistamines in an experimental model predictive of adverse clinical EEG effects. Arzneimittelforschung 1996; 46: 153–8

    PubMed  CAS  Google Scholar 

  440. Hondeghem LM, Lu HR, van Rossem K, et al. Detection of proarrhythmia in the female rabbit heart: blinded validation. J Cardiovasc Electrophysiol 2003; 14: 287–94

    PubMed  Article  Google Scholar 

  441. Kreutner W, Hey JA, Chiu P, et al. Preclinical pharmacology of desloratadine, a selective and nonsedating antihistamine H1 receptor antagonist. 2nd communication: lack of central nervous system and cardiovascular effects. Arzneimittelforschung 2000; 50: 441–8

    CAS  Google Scholar 

  442. Ducic I, Ko CM, Shuba Y, et al. Comparative effects of loratadine and terfenadine on cardiac K+ channels. J Cardiovasc Pharmacol 1997; 30: 42–54

    PubMed  CAS  Article  Google Scholar 

  443. Crumb Jr WJ. Loratadine blockade of K+ channels in human heart: comparison with terfenadine under physiological conditions. J Pharmacol Exp Ther 2000; 292: 261–4

    PubMed  CAS  Google Scholar 

  444. Rajamani S, Anderson CL, Anson BD, et al. Pharmacological rescue of human K+ channel long-QT2 mutations: human ether-a-go-go-related gene rescue without block. Circulation 2002; 105: 2830–5

    PubMed  CAS  Article  Google Scholar 

  445. Delgado LF, Pferferman A, Solé D, et al. Evaluation of the potential cardiotoxicity of the antihistamines terfenadine, astemizole, loratadine, and cetirizine in atopic children. Ann Allergy Asthma Immunol 1998; 80: 333–7

    PubMed  CAS  Article  Google Scholar 

  446. Abernethy DR, Barbey JT, Franc J, et al. Loratadine and terfenadine interaction with nefazodone: both antihistamines are associated with QTc prolongation. Clin Pharmacol Ther 2001; 69: 96–103

    PubMed  CAS  Article  Google Scholar 

  447. Weissenburger J, Noyer M, Cheymol G, et al. Electrophysiological effects of cetirizine, astemizole and d-sotalol model of long QT syndrome. Clin Exp Allergy 1999; 29 Suppl. 3: 190–6

    PubMed  CAS  Article  Google Scholar 

  448. Taglialatela M, Pannaccione A, Castaldo P, et al. Molecular basis for the lack of HERG K+ channel block-related cardiotoxicity by the H1 receptor blocker cetirizine compared with other second-generation antihistamines. Mol Pharmacol 1998; 54: 113–21

    PubMed  CAS  Google Scholar 

  449. Gilbert JD, Cahill SA, McCartney DG, et al. Predictors of torsades de pointes in rabbit ventricles perfused with sedating and nonsedating histamine H1-receptor antagonists. Can J Physiol Pharmacol 2000; 78: 407–14

    PubMed  CAS  Google Scholar 

  450. Sale ME, Barbey JT, Woosley RL, et al. The electrocardiographic effects of cetirizine in normal subjects. Clin Pharmacol Ther 1994; 56: 295–301

    PubMed  CAS  Article  Google Scholar 

  451. Simons FER, Silas P, Portnoy JM, et al. Safety of cetirizine in infants 6 to 11 months of age: a randomized, double-blind, placebo-controlled study. J Allergy Clin Immunol 2003; 111: 1244–8

    PubMed  CAS  Article  Google Scholar 

  452. Marino M, Glue P, Herron JM, et al. Lack of electrocardiographic effects of multiple high doses of desloratadine [abstract no. 999]. Allergy 2000; 55 Suppl. 63: 279

    Google Scholar 

  453. Banfield C, Padhi D, Glue P, et al. Electrocardiographic effects of multiple high doses of desloratadine [abstract no. 1119]. J Allergy Clin Immunol 2000; 104: 383

    Article  Google Scholar 

  454. Scherer CR, Lerche C, Decher N, et al. The antihistamine fexofenadine does not affect IKr-currents in a case report of drug-induced cardiac arrhythmia. Br J Pharmacol 2002; 137: 892–900

    PubMed  CAS  Article  Google Scholar 

  455. Pratt CM, Mason J, Russell T, et al. Cardiovascular safety of fexofenadine HCl. Am J Cardiol 1999; 83: 1451–4

    PubMed  CAS  Article  Google Scholar 

  456. Caballero R, Delpón E, Valenzuela C, et al. Effect of descarboethoxyloratadine, the major metabolite of loratadine, on the human cardiac potassium channel Kv1.5. Br J Pharmacol 1997; 122: 796–8

    PubMed  CAS  Article  Google Scholar 

  457. Lacerda AE, Roy M-L, Lewis EW, et al. Interactions of the nonsedating antihistamine loratadine with a Kv1.5-type potassium channel cloned from human heart. Mol Pharmacol 1997; 52: 314–22

    PubMed  CAS  Google Scholar 

  458. Delpón E, Valenzuela C, Gay P, et al. Block of human cardiac Kv1.5 channels by loratadine: voltage-, time- and use-dependent block at concentrations above therapeutic levels. Cardiovasc Res 1997; 35: 341–50

    PubMed  Article  Google Scholar 

  459. Crumb Jr WJ. Rate-dependent blockade of a potassium current in human atrium by the antihistamine loratadine. Br J Pharmacol 1999; 126: 575–80

    PubMed  CAS  Article  Google Scholar 

  460. Graft DF, Bernstein DI, Goldsobel A, et al. Safety of fexofenadine in children treated for seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2001; 87: 23–6

    Article  Google Scholar 

  461. Lindquist M, Edwards IR. Risks of non-sedating antihistamines [letter]. Lancet 1997; 349: 1322

    PubMed  CAS  Article  Google Scholar 

  462. Routledge PA, Lindquist M, Edwards IR. Spontaneous reporting of suspected adverse reactions to antihistamines: a national and international perspective. Clin Exp Allergy 1999; 29 Suppl. 3: 240–6

    PubMed  Article  Google Scholar 

  463. Craig-McFeely PM, Freemantle SL, Pearce GL, et al. QT lengthening and life-threatening arrhythmias associated with fexofenadine [letter]. Br J Clin Pract 2000; 50: 148

    CAS  Google Scholar 

  464. de Abajo FJ, Rodriguez LAG. Risk of ventricular arrhythmias associated with nonsedating antihistamine drugs. Br J Clin Pharmacol 1999; 47: 307–13

    PubMed  Article  Google Scholar 

  465. Atar S, Freedberg NA, Antonell D, et al. Torsades de pointes and QT prolongation due to a combination of loratadine and amiodarone. Pacing Clin Electrophysiol 2003; 26: 785–6

    PubMed  Article  Google Scholar 

  466. Good AP, Rockwood R, Schad P. Loratadine and ventricular tachycardia. Am J Cardiol 1994; 74: 207

    PubMed  CAS  Article  Google Scholar 

  467. Kuchar DL, Walker BD, Thorburn CW. Ventricular tachycardia following ingestion of a commonly used antihistamine. Med J Aust 2002; 176: 429–30

    PubMed  Google Scholar 

  468. Pinto YM, van Gelder IC, Heeringa M, et al. QT lengthening and life-threatening arrhythmias associated with fexofenadine [letter]. Lancet 1999; 353: 980

    PubMed  CAS  Article  Google Scholar 

  469. Giraud T. QT lengthening and arrhythmias associated with fexofenadine [letter]. Lancet 1999; 353: 2072

    PubMed  CAS  Article  Google Scholar 

  470. Kashyap AS, Kashyap S. Prolonged QTc time and ventricular arrhythmia with fexofenadine. Am J Cardiol 1999; 84: 1278–9

    PubMed  CAS  Google Scholar 

  471. Watanabe M, Kohge N, Kaji T. Severe hepatitis in a patient taking cetirizine. Ann Intern Med 2001; 135: 142–3

    PubMed  CAS  Google Scholar 

  472. Sánchez-Lombraña J, Alvarez RP, Sáez LR, et al. Acute hepatitis associated with cetirizine intake. J Clin Gastroenterol 2002; 34: 493–5

    PubMed  Article  Google Scholar 

  473. Fong DG, Angulo P, Burgart LJ, et al. Cetirizine-induced cholestasis. J Clin Gastroenterol 2000; 31: 250–3

    PubMed  CAS  Article  Google Scholar 

  474. Stingeni L, Carafini S, Agostinelli D, et al. Maculopapular and urticarial eruption from cetirizine. Contact Dermatitis 1997; 37: 249–50

    PubMed  CAS  Article  Google Scholar 

  475. Calista D, Schianchi S, Morri M. Urticaria induced by cetirizine. Br J Dermatol 2001; 144: 196

    PubMed  CAS  Google Scholar 

  476. Tella R, Gaig P, Bartra J, et al. Urticaria to cetirizine. J Invest Allergol Clin Immunol 2002; 12: 136–7

    CAS  Google Scholar 

  477. Karamfilov T, Wilmer A, Hipler U-C, et al. Cetirizine-induced urticarial reaction. Br J Dermatol 1999; 140: 979–80

    PubMed  CAS  Article  Google Scholar 

  478. Lew B-L, Haw C-R, Lee M-H. Cutaneous drug eruption from cetirizine and hydroxyzine. J Am Acad Dermatol 2004; 50: 953–6

    PubMed  Article  Google Scholar 

  479. Schröter S, Damveld B, Marsch WC. Urticarial intolerance reaction to cetirizine. Clin Exp Dermatol 2002; 27: 185–7

    PubMed  Article  Google Scholar 

  480. Inamadar AC, Palit A, Athanikar SB, et al. Multiple fixed drug eruptions due to cetirizine. Br J Dermatol 2002; 147: 2025–6

    Article  Google Scholar 

  481. Fraunfelder FW, Fraunfelder FT. Oculogyric crisis in patients taking cetirizine. Am J Ophthalmol 2004; 137: 355–7

    PubMed  Article  Google Scholar 

  482. Fraunfelder FW, Fraunfelder FT. Adverse ocular drug reactions recently identified by the National Registry of Drug-Induced Ocular Side Effects. Ophthalmology 2004; 111: 1275–9

    PubMed  CAS  Article  Google Scholar 

  483. Louis M-P, Héran I, Peyière H, et al. Two cases of gynaecomastia with cetirizine, a second-generation antihistamine. Thérapie 2004; 59: 163–4

    PubMed  Article  Google Scholar 

  484. Schötter B, Dösch, Kraemer DM. Severe hepatotoxicity after application of desloratadine and fluconazole. Acta Haematol 2003; 110: 43–4

    Article  Google Scholar 

  485. Welch D, Ousler III GW, Nally LA, et al. Ocular drying associated with oral antihistamines (loratadine) in the normal population: an evaluation of exaggerated effect. Adv Exp Med Biol 2002; 506(B): 1051–5

    PubMed  CAS  Article  Google Scholar 

  486. Schiano TD, Bellary SV, Cassidy MJ, et al. Subfulminant liver failure and severe hepatotoxicity caused by loratadine use. Ann Intern Med 1996; 125: 738–40

    PubMed  CAS  Google Scholar 

  487. Pionetti CH, Kien MC, Alonso A. Fixed drug eruption due to loratadine. Allergol Immunopathol (Madr) 2003; 31: 291–3

    CAS  Article  Google Scholar 

  488. Bonanni L, Parmiani S, Sturbini S. Glottis oedema due to loratadine. Allergy 2004; 59: 116–7

    PubMed  CAS  Article  Google Scholar 

  489. Farinas E, Honig P. Upper gastrointestinal obstruction associated with Claritin-D 24 hour extended release tablets. J Allergy Clin Immunol 1997; 100: 427–8

    PubMed  CAS  Article  Google Scholar 

  490. Manda B, Drinkard CR, Shatin D, et al. The risk of esophageal obstruction associated with an anti-allergy medication (Claritin-D® 24-Hour-original formulation). Pharmacoepidemiol Drug Saf 2004; 13: 29–34

    PubMed  CAS  Article  Google Scholar 

  491. Ransom JH. Esophageal retention of loratadine plus pseudoephedrine extended-release tablets (Claritin-D 24 hour). J Allergy Clin Immunol 1998; 101: 287–8

    PubMed  CAS  Article  Google Scholar 

  492. Ridout SM, Tariq SM. Cetirizine overdose in a young child. J Allergy Clin Immunol 1997; 99: 860–1

    PubMed  CAS  Article  Google Scholar 

  493. Gokel Y, Satar S, Sebe A. Loratadine toxicity. Am J Emerg Med 2000; 18: 639–40

    PubMed  CAS  Google Scholar 

  494. Spiller HA, Villalobos D, Benson BE, et al. Retrospective review of cetirizine (Zyrtec) ingestion [letter]. J Toxicol Clin Toxicol 2002; 40: 525–6

    PubMed  Google Scholar 

  495. Simons FER. H1-antihistamines in children. Clin Allergy Immunol 2002; 17: 437–64

    PubMed  CAS  Google Scholar 

  496. Mazzotta P, Loebstein R, Koren G. Treating allergic rhinitis in pregnancy: safety considerations. Drug Saf 1999; 20: 361–75

    PubMed  CAS  Article  Google Scholar 

  497. Seto A, Einarson T, Koren G. Pregnancy outcome following first trimester exposure to antihistamines: meta-analysis. Am J Perinatal 1997; 14: 119–24

    CAS  Article  Google Scholar 

  498. Blaiss MS. Management of rhinitis and asthma in pregnancy. Ann Allergy Asthma Immunol 2003; 90 Suppl. 3: 16–22

    PubMed  CAS  Article  Google Scholar 

  499. Dombrowski MP, Huff R, Lipkowitz M, et al. The use of newer asthma and allergy medication during pregnancy. Ann Allergy Asthma Immunol 2000; 84: 475–80

    Article  Google Scholar 

  500. Diav-Citrin O, Schechtman S, Aharonovich A, et al. Pregnancy outcome after gestational exposure to loratadine or antihistamines: a prospective controlled cohort study. J Allergy Clin Immunol 2003; 111: 1239–43

    PubMed  CAS  Article  Google Scholar 

  501. Moretti ME, Caprara D, Coutinho CJ, et al. Fetal safety of loratadine use in the first trimester of pregnancy: a multicenter study. J Allergy Clin Immunol 2003; 111: 479–83

    PubMed  CAS  Article  Google Scholar 

  502. Keleş N. Treatment of allergic rhinitis during pregnancy. Am J Rhinol 2004; 18: 23–8

    PubMed  Google Scholar 

  503. Einarson A, Bailey B, Jung G, et al. Prospective controlled study of hydroxyzine and cetirizine in pregnancy. Ann Allergy Asthma Immunol 1997; 78: 183–6

    PubMed  CAS  Article  Google Scholar 

  504. Einarson A, Levichek Z, Einarson TR, et al. the antiemetic effect of cetirizine in pregnancy [letter]. Ann Pharmacother 2000; 34: 1486–7

    PubMed  CAS  Google Scholar 

  505. Hilbert J, Radwanski E, Affrime M, et al. Excretion of loratadine in human breast milk. J Clin Pharmacol 1988; 28: 234–9

    PubMed  CAS  Google Scholar 

  506. Lucas Jr BD, Purdy CY, Scarim SK, et al. Terfenadine pharmacokinetics in breast milk of lactating women. Clin Pharmacol Ther 1995; 57: 398–402

    PubMed  CAS  Article  Google Scholar 

  507. Ward RM, Bates BA, Benitz WE, et al. The transfer of drugs and other chemicals into human milk. Pediatrics 2001; 108: 776–89

    Google Scholar 

  508. Ament PW, Paterson A. Drug interactions with the nonsedating antihistamines. Am Fam Physician 1995; 56: 223–30